EASI Drugs in the Streets of Colombia: Modeling Heterogeneous and Endogenous Drug Preferences

Santiago Montoya-Blandón*

Andrés Ramírez–Hassan[†]

March 27, 2025

Abstract

The response of illicit drug consumers to large-scale policy changes, such as legalization, is heavily mediated by their demand behavior. Since individual drug use is driven by many unobservable factors, accounting for unobserved heterogeneity is crucial for modeling demand and designing targeted public policies. This paper introduces a finite Gaussian mixture of Exact Affine Stone Index (EASI) demand systems to estimate the joint demand for marijuana, cocaine, and basuco (cocaine residual or "crack") in Colombia, accounting for corner solutions and endogenous price variation. Our results highlight the importance of unobserved heterogeneity in identifying reliable price elasticities. The method reveals two regular consumer subpopulations: "safe" (recreational) and "addict" users, with the majority falling into the first group. For the "safe" group, whose estimates are precise and nationally representative, all three drugs exhibit unitary price elasticities, with cocaine being complementary to marijuana and basuco an inferior substitute to cocaine. Given the low production cost of marijuana in Colombia, legalization is likely to drive prices down significantly. Our counterfactual analysis suggests that a 50% price decrease would result in a \$363 USD gain in utility-equivalent expenditure per representative consumer, \$120 million USD in government tax revenue, and a \$127 million USD revenue loss for drug dealers. Legalization, therefore, has the potential to reduce the incentive for drug-related criminal activity, the current largest source of violent crime in Colombia.

JEL: D12, C11, C35.

Keywords: Bayesian analysis, Demand systems, Drug consumption, Finite mixture models, Price endogeneity.

^{*}Adam Smith Business School, University of Glasgow. Room 620, ASBS Building, 2 Discovery Place, Glasgow, United Kingdom, G11 6EY. Email: santiago.montoya-blandon@glasgow.ac.uk

[†]School of Finance, Economics and Government. Valor Público and OMEGA research group, Universidad EAFIT, Medellín, Colombia. E-mail: aramir21@eafit.edu.co. Carrera 49 7 Sur-50, phone: + 57 2619500

1 Introduction

Drug consumption is a growing market that encompasses an ever-larger number of users worldwide. According to the 2023 report of the United Nations Office of Drug and Crimes (UNODC, 2023), the global number of users of different drugs in 2022 was 219 million for marijuana (representing around 4.8% of the adult population), followed by opioids (64 million), amphetamines (36 million), cocaine (22 million), and ecstasy (20 million). In order to cope with the public health outcomes from increasing drug consumption, several nations across the world have enacted laws legalizing recreational drug use. Specifically for cannabis, the most-widely consumed substance, recreational use has been legalized in Canada, Georgia, Germany, Luxembourg, Malta, Mexico, South Africa, Thailand, Uruguay, and 24 US states, with many other nations currently considering similar policies. Assessing the impacts of these policies ex-ante requires understanding how consumers might react to variations in the prices of drugs associated with their legalization (Becker et al., 2006, Hall and Lynskey, 2016). Additionally, joint policy interventions are usually employed to support the legalization or decriminalization of substances. These interventions are more effective if they target specific segments of the population that face particular necessities. Characterizing population segments that are similar in their preferences for drugs can directly translate to more effective targeting of interventions aimed at these groups.

This paper aims to analyze the demand for illicit drugs among regular consumers in Colombia, taking preference heterogeneity into account to identify potentially diverse responses to price changes, such as those associated with the possible legalization of marijuana in the country. These price responses are used to evaluate the potential effects of marijuana legalization on consumer welfare, government collection, and drug dealers' revenue. The latter effects are particularly important as policymakers advocate legalization as a strategy to reduce drug profitability, which is often linked to violent crime (Queirolo et al., 2019, Gavrilova et al., 2019). Evidence supports the claim that marijuana legalization introduces legal competition in the drug market, which decreases profitability and can help reduce crime (Huber III et al., 2016, Dragone et al., 2019, Brinkman and Mok-Lamme, 2019, Burkhardt and Goemans, 2019, Wu et al., 2020, Anderson and Rees, 2023), particularly violent crimes associated with drug trafficking and resolving disputes (Burkhardt and Goemans, 2019, Chu and Townsend, 2019, Gavrilova et al., 2019, Wu et al., 2022, Anderson and Rees, 2023). The issue of violent drug crime is of great relevance in Colombia, where homicide rates and violence linked to drug trafficking are pronounced (Puerta-Cuartas and Ramírez-Hassan, 2024).

Moreover, the Colombian case is particularly significant as it is one of the world's leading producers of marijuana and cocaine (UNODC, 2021), resulting in relatively low prices and widespread access to these substances. The research question is also timely, as the Colombian national congress recently debated the legalization of recreational marijuana in 2023 but failed to secure sufficient votes in the final round of discussions.¹ According to our main dataset of interest, a 2019 nationally representative survey of Colombians aged 12 to 65 regarding their consumption of psychoactive substances, marijuana is found to be the most consumed drug, followed by cocaine, and then cocaine residue (known locally as "basuco" or colloquially as "crack" in the United States), with other drugs showing only trace amounts of measurable national consumption. Therefore, in this research we focus on studying the demand for these three most-consumed drugs in Colombia.²

¹https://www.reuters.com/world/americas/colombia-senate-votes-down-recreational-marijuana-bill-2 023-06-21/.

 $^{^{2}}$ Currently, possession for personal use is decriminalized in Colombia, allowing individuals to carry up to 20 grams of marijuana and 1 gram of cocaine or basuco.

Demand systems serve as essential tools for learning about consumer behavior and its responses to diverse market conditions (Deaton and Muellbauer, 1980). There is extensive previous literature using demand systems to understand consumption patterns for some addictive substances, particularly alcohol and tobacco (Thies and Register, 1993, Deza, 2023). However, there there is a conspicuous gap in the literature regarding the study of joint drug consumption patterns, likely due to issues of data availability and general attitudes towards illicit substances. A key contribution of our analysis is to examine not just a single drug in isolation, but the joint demand for cannabis, cocaine, and basuco. This broader perspective is critical as it enables us to explore whether these substances exhibit substitution or complementary relationships and whether these patterns differ across population groups. A complementary pattern from "softer" drugs like marijuana to "harder" drugs like cocaine is commonly known as the *gateway hypothesis* (Kandel, 1975, Lynskey and Agrawal, 2018), and our econometric framework can inform about such relationship in the data.

An additional feature of demand systems is that they allow us to study demand under counterfactual scenarios. That is, we can construct conterfactual price scenarios associated with the legalization of marijuana, to account for mixed effects of legalization on marijuana price (due to shifts away from the black market structure). Evidence highlights varied outcomes depending on the region, market conditions, and regulatory frameworks. For example, the Uruguayan government deliberately kept marijuana prices low to undercut the black market, while in Canada, the price of marijuana increased by 32% after legalization, primarily due to regulatory factors.³ In the specific context of Colombia, the production cost of one gram is approximately US¢1 (Vélez-Torres et al., 2021). In contrast, the current illegal market price is around US¢83 (see descriptive statistics from our dataset in Table 1). This significant disparity indicates a considerable potential for lowering marijuana prices in a legalized market. Thus, the price elasticities of drug dealers' product offerings are critically important for assessing their potential revenue impacts in a post-legalization scenario.

Previous studies additionally and heavily emphasize the relevance of heterogeneity, in both observable and unobservable factors, to understanding complex patterns found in demand data (Duffy, 2003, Lacruz and Molina, 2009, Aristei and Pieroni, 2010, Tauchmann et al., 2013, Bokhari and Mariuzzo, 2018). In estimation of demand systems, researchers often rely on observable features to approximate unobserved preference heterogeneity. This has been implemented in the literature through the incorporation of interaction terms (Blundell et al., 1993, Moro and Sckokai, 2000) or by categorizing individuals *ex-ante* using observable features (Bonnet and Réquillart, 2013). Other studies address unobserved heterogeneity using random parameter models (von Haefen et al., 2004, Lewbel and Pendakur, 2009) or segmentation algorithms (Bertail and Caillavet, 2008, Kehlbacher et al., 2020). In the former, heterogeneity emerges from parameter values that vary across cross-sectional units according to some distribution function, while the latter assumes that the units are clustered into sub-populations, each with similar preferences within clusters and distinct preferences across clusters.

Our paper contributes to the literature by studying demand for illicit drugs using a novel data set in a particularly relevant developing country, proposing a new estimation framework based on a microeconomically founded model that takes unobserved heterogeneity, corner (zero) solutions, and endogeneity into account. Specifically, we propose a Bayesian inferential framework that allows for clusters of unobserved preference heterogeneity through a finite mixture of Exact Affine Stone Index (EASI) demand systems. The Bayesian framework allows us some additional advantages that are relevant for our application. First, we can easily impose and test relevant microeconomic restrictions such as symmetry, strict cost monotonicity and concav-

³See the official website from Statistics Canada on the price of cannabis post-legalization: https://www150.sta tcan.gc.ca/n1/daily-quotidien/190710/dq190710c-eng.htm.

ity of the cost function, which ensure the recovered demand functions satisfy standard theoretical conditions (Ramírez-Hassan, 2021, Ramírez-Hassan and López-Vera, 2024). Second, it allows us to account for corner outcomes where individuals can decide not to consume a given set of goods, which is relevant as many consumers in our sample only report consuming one illicit drug out of the three we consider. Third, it becomes straightforward to include membership to unobserved heterogeneity clusters and associated probabilities as parameters to perform data-driven consumer segmentation and heterogeneous drug responses. Finally, it allows us to obtain inference on the structural quantities of interest, such as price-demand elasticities or predicted revenue under counterfactual scenarios as a by-product of estimation, all of which are highly non-linear functions of data and model parameters. For further details on Bayesian estimation of demand systems, see Tiffin and Arnoult (2010), Kasteridis et al. (2011), Kehlbacher et al. (2020), Jacobi et al. (2021), Ramírez-Hassan (2021).

Applying our methodology to the analysis of demand for marijuana, cocaine and basuco in Colombia, results suggest that unobserved heterogeneity is crucial to obtaining precise and economically relevant demand behaviour when taking into account censoring and price endogeneity. Our method automatically partitions our sample into two sub-populations: "safe" and "addict" consumers. The former group represents the largest user segment, presenting sensible and economically rational patterns of drug demand. In contrast, the latter group has large consumption of the cocaine-based substances and scores highly in the survey questions meant to screen for substance addiction, providing a rational behind our labels. In addition, we find for the "safe" group that all three own-price elasticities for each drug are statistically indistinguishable from unity, with a complementary relationship between marijuana and cocaine and an substitution between higher-quality cocaine and lower-quality residual.

In the most likely scenario that the legalization of marijuana results in a 50% decrease to the price of marijuana (given the high illegal price markup in Colombia), our estimates suggest that commercial sale of marijuana would imply a considerable increase in marijuana consumption among regular consumers, with relatively much smaller effects for cocaine and basuco. This increase is valued by consumers at approximately \$363 USD of utility-equivalent expenditure as measured by the Equivalent Variation of the price change. In addition, we find a high probability that the government will capture a large amount of the legal market resulting in considerable revenue gains even in the face of the reduced post-legalization price. This gain is at the expense of a decrease in drug dealers' revenues due to the entry of legal competitors, with dealers having to adjust their product offerings in response. The number of users required to offset such a revenue decline, around 130% new drugs users compared to pre-legalization, is not likely to be realized based on international legalization experiences. Taken together, these findings suggest a marijuana legalization policy in Colombia is likely to succeed at disincentivizing drug-related criminal activity; the current largest source of homicides in the country.

This paper connects with a wealth of previous literature on the demand systems, demand for addictive substances, unobserved preference heterogeneity, among others. An important advantage of demand systems is their ability to consider joint consumption across categories of goods as well as providing insight into determinants of these behaviors. For instance, Duffy (2003) uses the Quadratic Almost Ideal Demand system (QAID, Banks et al., 1997) to investigate consumer spending patterns in the United Kingdom, challenging the prevailing assumption that advertising significantly influences preferences, particularly for products like tobacco. Aristei and Pieroni (2010) conduct an innovative exploration of alcohol and tobacco consumption patterns in Italy, effectively addressing criticisms related to unmeasured preferences and correlated unobserved heterogeneity, shedding some light on the joint determinants of these behaviors. Other recent research adds further structure to the models in order to dive deeper into the determinants of addictive substance consumption. For example, Lacruz and Molina (2009) give an in-depth examination of alcohol demand among youth in Spain, highlighting the impact of factors such as income, prices, and the addictive nature of alcohol. Using German survey data, Tauchmann et al. (2013) challenge the notion of tobacco and alcohol as substitutes by employing a structural model to directly estimate their interdependence, with profound implications for anti-smoking policies. Bokhari and Mariuzzo (2018) considers pharmaceuticals, as they are legal but still potentially addictive substances. This paper analyzes the demand for drugs used to treat attention deficit hyperactivity disorder (ADHD) through the lens of demand systems, focusing on the impact of pharmaceutical mergers. Their study emphasizes the importance of selecting the demand model when evaluating the effects of large-scale market changes, particularly to capture drug substitution patterns. Collectively, these findings highlight the value of demand system analysis in understanding drug consumption patterns and informing effective policy strategies across a wide range of substances.

Unobserved heterogeneity in the demand for illicit drugs is particularly relevant when testing the gateway hypothesis. DeSimone (1998) found evidence that marijuana consumption can potentially lead to the consumption of other drugs, where they allow for structural estimates of unobserved heterogeneity to affect both marijuana and cocaine. van Ours (2003, 2006) provide evidence of a causal relationship between cannabis and cocaine use, where the use of multiple drugs is generally driven by unobserved individual characteristics. Bretteville-Jensen et al. (2008) argues that the empirical association between cannabis and heroin use could be spurious. The authors interpret unobserved heterogeneity as "antisocial behavior" and explain that this could simultaneously affect both cannabis and heroin use. Fergusson et al. (2006) find that controlling for confounding time trends and dynamic factors reduces the strength of the association between cannabis use and other drugs. However, a stronger association between the frequency of cannabis use and other illicit drugs remains even after controlling for unobserved dynamic effects. Bretteville-Jensen et al. (2008) agree that the gateway effect diminishes greatly when unobserved factors are considered, and Melberg et al. (2010) examine the gateway hypothesis explaining that factors like traumatic childhood experiences could be associated with both cannabis and heroin use. If this is the case, the causal impact of cannabis use on the use of harder drugs would be confounded by the presence of the unobserved trauma factor, mistakenly leading to the conclusion that cannabis serves as a gateway to other drugs. Deza (2015) explores the dynamic patterns of drug use, distinguishing between the effects of prior drug consumption and unobserved heterogeneity. The former implies that past experiences influence future choices, while the latter suggests inherent tendencies toward drug consumption in certain individuals. This study finds evidence supporting the hypothesis that consumption of hard drugs complements the consumption of alcohol and marijuana. Jorgensen and Wells (2021) found that marijuana is not a reliable gateway cause of illicit drug use when taking unobserved effects into account; meaning prohibition policies are unlikely to reduce illicit drug use. In summary, the literature finds that heterogeneous effects are relevant when analyzing demand of illicit drugs, particularly in testing the gateway hypothesis, and that there is not conclusive evidence about the relationship between marijuana use and use of "harder" drugs like cocaine.

After this introduction, we present in Section 2 our data set, descriptive statistics, and some preliminary descriptive patterns. Section 3 shows the microeconomic and econometric framework, and Section 4 shows the econometric results. We present in Section 5 counterfactual exercises from implied price changes after a legalization policy on consumer welfare, government revenue and drug dealers' illegal market size. Section 6 presents our policy recommendations based on results and concluding remarks.

2 Descriptive statistics of drug demand in Colombia

We use the National Survey of the Consumption of Psychoactive Substances performed in 2019 (ENCSPA from its name in Spanish) by the Colombian National Administrative Department of Statistics. This is a nationally representative survey aiming to measure the consumption of legal and illegal psychoactive substances. Individuals between 12 and 65 years old from several municipalities were randomly selected, and the enumerators privately performed the survey. If the chosen individual was absent during the survey, the enumerator should return later. The survey resulted in a total sample of 49,439 individuals, representative of approximately 23.6 million individuals, which is equivalent to roughly the total urban Colombian population in 2019 within the considered age range.

Our primary objective is to examine the potential effects of significant drug price variations in Colombia on the consumption of marijuana and harder drugs (specifically cocaine and basuco); for example, as a result of a marijuana legalization policy. These three drugs were identified as the most relevant illicit drugs in Colombia in terms of consumption and expenditure. Therefore, we limit our sample to current regular consumers, identified in the survey as those individuals who report consuming at least one of the three illicit substances in the month preceding the interview. Limiting our sample to consumers results in a total of 1,236 users that are representative of 633,490 users nationwide.

2.1 Drug market

According to the *ENCSPA* survey, the total national expenditure on marijuana, cocaine, and basuco in 2019 was USD 226.3 million among regular users.⁴ Figure 1 shows the share of total expenditure by age groups and drug of choice. We see that individuals in their twenties spend the most, approximately 51.9%, followed by individuals in their thirties (20.1%), teenagers (14.7%), forties (6.9%) and fifties (6.4%). This is concerning as younger individuals spend the most. We also see in this figure that marijuana represents by far the most relevant expenditure. Conditional on age group, marijuana shares range between 70% (fifties) and 92.7% (twenties). We see that basuco represents the lowest share, ranging between 0.0% (teenagers) and 3.7% (fifties). Cocaine remains as in-between these two substances, with the largest expenditure share coming from individuals in their fifties spending 26.4% of their drug budget in this substance, with a concerningly large share remaining for both teenagers and young adults (14.7% and 6.3%, respectively).

Expenditure is composed of three elements: quantities, prices, and total size of the market. Turning our attention first to market size, we classify the total number of regular users according to their drug of choice, resulting in 550,786 total marijuana users, with 73,578 for cocaine and 9,126 for basuco. Figure 2 shows the distribution of these users by age group. We observe again that individuals in their twenties represent the largest share (53.0%), followed by individuals in their thirties (18.9%), teenagers (15.1%), forties (7.4%) and fifties (5.5%). We also see again that marijuana gets the largest share, ranging between 88.4% (twenties) and 77.2% (forties). The second largest is associated with cocaine, where its share ranges between 21.0% (forties) and 9.4% (teenagers). Finally, there is basuco, whose share ranges between 5.2% (fifties) and 0.2% (teenagers). It is concerning that most of drug users are individuals less than thirty years old, and that older individuals have higher concentrations of hard drug use.

Table 1 shows descriptive statistics for individual-level expenditure shares, quantities consumed and prices faced in the market for drugs. Marijuana's share is the largest (86.9%), followed by cocaine (10.7%). We

⁴We use the average exchange rate in 2019 (COP/USD 3,282.39) to convert all values in Colombian pesos to US dollars throughout the paper (BanRep, 2019).



Figure 1: Shares of total expenditure on drugs in Colombia by age groups

Notes: Total drug market expenditure in Colombia was approximately USD 226.3 million in 2019. Individuals in their twenties represent the most relevant expenditure share followed by individuals in their thirties. Marijuana has the largest share of expenditure in all age groups.

also report the proportion of zeros in the sample, where marijuana has the lowest figure (6.5%), while basuco has the highest (95.5%). This highlights the importance of taking into account the censoring issue in the econometric framework, as standard models cannot account for the exceeding share of consumers that do not demand some of the drugs.

Conditional on the consumption of each drug, the average monthly consumption of marijuana, cocaine, and basuco is 43.1, 6.6, and 21.1 grams, respectively. However, there is substantial variability. For instance, one individual reports consuming 20 grams (joints) of marijuana per day. The unconditional average monthly consumption of marijuana, cocaine, and basuco is 39.8, 1.3, and 0.95 grams, respectively. This is because most individuals consume only marijuana, as illustrated in Figure 4. The average marijuana price is 83.3 USD ϕ/gr . with a range from 15.3 USD ϕ/gr . to 305.4 USD ϕ/gr . This high variability in prices is also present in the other drugs: cocaine prices range from 61.1 USD ϕ/gr . to 1,221.8 USD ϕ/gr ., and basuco from 30.5 USD ϕ/gr . to 305.4 USD ϕ/gr . This heterogeneity is largely attributed to differences in drug quality and suppliers' location.

Due to the clear heterogeneity exhibited in both users and expenditure due to age, we consider the distribution of quantities and price similarly disaggregated by age groups for each drug in Figure 3. We observe that there is some degree of heterogeneity regarding consumption of marijuana and basuco according to the left panel in Figure 3. The average consumption of marijuana ranges between 25.1 (fifties) and 51.2 (thirties) joints per month, and the average consumption of basuco ranges between 2.0 (teenagers) and 29.9 (thirties) grams per month. On the other hand, the average consumption of cocaine is fairly homogeneous, around 6.7 grams per month, except for individuals in their twenties (4.5 grams per month). We note that individuals



Figure 2: Shares of drug users in Colombia by age groups and drugs

Notes: Total drug users in Colombia amounted to 633,490 in 2019. We classify individuals according to their drug consumption. Individuals in their twenties represent the largest share of total users followed by individuals in their thirties and teenagers. Marijuana has the largest share of users in all age groups.

Figure 3: Drug consumption and prices among users in Colombia by age groups and drugs



Notes: Left panel: Average consumption per month in grams. Right panel: Average price per gram in 2019 USD. There is some degree of heterogeneity regarding drug consumption by age group. Individuals in their thirties consume the most in all three drugs. The average consumption of marijuana is the largest followed by basuco, except among teenagers. The average drug prices are relatively homogeneous among age groups. Cocaine is the most expensive drug per gram, while marijuana and basuco have similar prices per gram.

Shares (percentage points, pp.)	Mean	Std. Dev.	Proportio	on with no expenditure
Marijuana	86.86	29.95		6.47
Cocaine	10.75	27.15		80.74
Basuco	2.40	13.86		95.55
Quantity (grams per month)	Mean	Std. Dev.	Min.	Max.
Marijuana	39.80	74.78	0.00	600.00
Cocaine	1.28	5.04	0.00	50.00
Basuco	0.95	7.97	0.00	150.00
Prices (cents per gram, USD ϕ/gr .)	Mean	Std. Dev.	Min.	Max.
Marijuana	83.31	53.10	15.27	305.44
Cocaine	309.32	162.06	61.09	1,221.75
Basuco	73.32	37.44	30.54	305.44

Table 1: Summary statistics for shares of drug consumption and prices

Notes: Total sample size includes 1,236 consumers from ENCSPA survey in Colombia. Monthly quantity is conditional on consumption and prices are given in 2019 USD. Marijuana is the most relevant drug expenditure, followed by cocaine. There is a high level of censoring, particularly in basuco, and also a high variability regarding drug prices faced by individuals.

in their thirties have the largest consumption of all the three drugs, and individuals in their twenties have the second largest consumption of marijuana (43.2 joints) and basuco (20.1 grams).

The right panel of Figure 3 shows the distribution of average prices by age group among regular users. There is still some small heterogeneity remaining for the prices per dose among age groups. The most expensive drug is cocaine, where its average price ranges between USD/gram 2.4 (forties) and USD/gram 3.3 (teenagers), with marijuana and basuco having similar prices per doses. Marijuana prices faced by consumers ranged between USD/gram 0.77 (teenagers) and USD/gram 1.02 (fifties), and basuco prices ranged between USD/gram 0.61 (teenagers) and USD/gram 0.94 (forties). It is concerning that teenagers get the lowest average prices of marijuana and basuco. Price variation remains at the individual level due to both observed and unobserved factors, which we exploit in our modelling strategy to construct accurate demand estimates.

2.2 Consumer characteristics

The previous aggregated analysis grouped individuals by their drug of choice to obtain market-level statistics. However, our analysis accounts for the fact that a user may consume multiple drugs. Figure 4 shows the distribution of users across the consumption bundles implied by our considered drug choices (including non-regular consumers for reference). This figure reveals that 97.5% of individuals report not regularly consuming any of the three drugs. Among the remaining 2.5%, 2.34% are regular marijuana users, 0.55% consume cocaine, and 0.11% consume basuco. The majority consume only marijuana (1.95%), followed by those who consume both marijuana and cocaine regularly (0.33%), those who exclusively consume cocaine (0.11%), and those who consume all three drugs (0.06%). Notably, the second-largest group consists of individuals who jointly consume marijuana and cocaine, suggesting potential complementarity between these substances on the extensive margin. In contrast, basuco users represent the smallest share, which aligns with expectations

given its high addictiveness and severe adverse health effects.



Figure 4: Distribution of consumption bundles implicit in the ENCSPA survey

Notes: Total sample includes 49,439 individuals, representative of approximately 23.6 million, approximately the Colombian urban population between 12 and 65 in 2019. Most of individuals report not to consume any drug regularly. Individuals who just consume marijuana represent the largest share, followed by individuals who consume marijuana and cocaine, and then individuals who consume all three drugs.

Table 2 presents descriptive statistics for demographic characteristics available in the survey. We see from this table that the representative (modal) regular drug user is a male that has drug dealers in his neighborhood, lives in a low-socioeconomic stratum, his friends also use drugs, consumes alcohol and cigarettes jointly, is 29 years-old, studied for 12 years, and is currently employed. This person spends on average USD 30.7 per month in drugs, and has access to marijuana, cocaine and basuco. This person has used marijuana per 11 years, , reports having a good physical and mental health, and has a high risk perception about drugs.

The bottom set of variables in Table 2 consists of instruments based on the consumers' geo-referenced location.⁵ Using Gaussian kernels with a 1,000-meter bandwidth centered at the longitude/latitude coordinates of each regular consumer in our sample, we can construct a distance-weighted average of the number of drug dealers captured in the previous year, as well as the average prices of marijuana and cocaine. On average, we find approximately 482 drug dealer captures, with a large standard deviation of 660 captures. This large number reflects the prevalence of drug dealing in Colombia and how concentrated it is in specific urban areas (Puerta-Cuartas and Ramírez-Hassan, 2024). The marijuana and cocaine prices elicited from drug dens near consumers are very similar to those reported in Table 1, but they are more precisely measured and are less prone to measurement error (Zhen et al., 2014). The role of these instruments is expanded upon in sections 3 and 4.

To sum up, individuals in their twenties represent the largest market share, where marijuana is the most relevant expenditure (see Figure 1). Although there is some degree of heterogeneity in average consumption,

⁵Location of surveyed participants is only available through on-site data haven access from the National Administrative Department of Statistics (DANE, from its name in Spanish).

Access indicators $Marijuana$ 0.99 0.05 0 1 Cocaine 0.79 0.41 0 1 Basuco 0.54 0.50 0 1 Dealer presence 0.51 0.50 0 1 Consumer in network 0.94 0.24 0 1 Drug purchase sources indicators 0.09 0.29 0 1 Obtained marijuana network 0.03 0.48 0 1 Obtained cocaine in person 0.03 0.60 0.49 0 1 Obtained cocaine in person 0.03 0.11 0.30 0 1 Obtained basuco through friends 0.02 0.14 0 1 Obtained basuco through friends 0.02 0.14 0 1 Marijuana 0.89 0.31 0 1 Marijuana 0.89 0.24 0.3 1 Medium risk 0.05 <th>Variable</th> <th>Mean</th> <th>Std. Dev.</th> <th>Min.</th> <th>Max.</th>	Variable	Mean	Std. Dev.	Min.	Max.
Marijuana 0.99 0.05 0 1 Cocaine 0.79 0.41 0 1 Basuco 0.54 0.50 0.50 0 1 Dealer presence 0.51 0.50 0.50 0 1 Consumer in network 0.94 0.02 0 1 Obtained marijuana online 0.05 0.48 0 1 Obtained marijuana in person 0.35 0.48 0 1 Obtained marijuana in person 0.10 0.30 0 1 Obtained cocaine in person 0.10 0.30 0 1 Obtained basuco onine 0.03 0.18 0 1 Obtained basuco onine 0.03 0.18 0 1 Obtained basuco onine 0.03 0.18 0 1 Obtained basuco onine 0.89 0.31 0 1 Obtained basuco onine 0.89 0.31 0 1 Marijuana 0.89	Access indicators				
Cocaine 0.79 0.41 0 1 Basuco 0.54 0.50 0 1 Dealer presence 0.51 0.50 0 1 Consumer in network 0.94 0.24 0 1 Drug purchase sources indicators	Marijuana	0.99	0.05	0	1
Basuco 0.54 0.50 0 1 Dealer presence 0.51 0.50 0 1 Consumer in network 0.94 0.24 0 1 Dytag purchase sources indicators 1 1 Obtained marijuana netrough friends 0.09 0.29 0 1 Obtained marijuana person 0.35 0.48 0 1 Obtained cocaine online 0.03 0.16 0 1 Obtained cocaine in person 0.10 0.30 0 1 Obtained basuco online 0 0.03 0 1 Obtained basuco in person 0.03 0.18 0 1 Obtained basuco in person 0.24 0.43 0 1 Basuco 0.24 0.43 0 1 Cocaine 0.58 0.49 0 1 Basuco 0.02 0.14 0 1 Merijuana 0.05 0.22 0 1 <t< td=""><td>Cocaine</td><td>0.79</td><td>0.41</td><td>0</td><td>1</td></t<>	Cocaine	0.79	0.41	0	1
Dealer presence 0.51 0.50 0 1 Consumer in network 0.94 0.24 0 1 Dbrag purchase sources indicators 1 Obtained marijuana in person 0.35 0.48 0 1 Obtained marijuana in person 0.03 0.16 0 1 Obtained cocaine in person 0.10 0.30 0 1 Obtained cocaine through friends 0.10 0.30 0 1 Obtained cocaine through friends 0.02 0.14 0 1 Obtained basuco online 0 0.03 0.1 1 Obtained basuco in person 0.03 0.18 0 1 Obtained basuco through friends 0.02 0.14 0 1 Mariyana	Basuco	0.54	0.50	0	1
Consumer in network 0.94 0.24 0 1 Drug purchase sources indicators Obtained marijuana in person 0.35 0.48 0 1 Obtained marijuana through friends 0.60 0.49 0 1 Obtained cocaine online 0.03 0.16 0 1 Obtained cocaine in person 0.10 0.30 0 1 Obtained cocaine in person 0.10 0.30 0 1 Obtained basuco online 0 0.03 0.1 1 Obtained basuco nine person 0.03 0.18 0 1 Obtained basuco through friends 0.02 0.14 0 1 Obtained basuco through friends 0.02 0.14 0 1 Marijuana 0.89 0.31 0 1 Genaine 0.02 0.14 0 1 Marijuana 0.89 0.32 0.14 0 1 Medium risk 0.02 0.14 <td>Dealer presence</td> <td>0.51</td> <td>0.50</td> <td>0</td> <td>1</td>	Dealer presence	0.51	0.50	0	1
Drug purchase sources indicatorsObtained marijuana in person 0.09 0.29 0 1 Obtained marijuana in person 0.35 0.48 0 1 Obtained cocaine online 0.03 0.16 0 1 Obtained cocaine in person 0.10 0.30 0 1 Obtained cocaine in person 0.10 0.30 0 1 Obtained basuco online 0 0.03 0 1 Obtained basuco in person 0.03 0.18 0 1 Obtained basuco through friends 0.02 0.14 0 1 Obtained basuco through friends 0.02 0.14 0 1 Basuco 0.24 0.43 0 1 0 Basuco 0.24 0.43 0 1 1 Marijuana 0.58 0.49 0 1 1 Medium risk 0.05 0.22 0 1 1 Hedin risk 0.03 0.26 0 1 1 Hedin risk 0.33 0.26 0 1 1 High risk 0.33 0.26 0 1 1 Marijuana 0.8 9.80 0 50 0 1.44 6.12 0.7 Sauco 1.44 6.12 0.7 7.78 0 4 4 1 Hedin risk 0.37 $5.8.24$ 0.26 48.70 1 1 Parent and other demographics 1.24 <t< td=""><td>Consumer in network</td><td>0.94</td><td>0.24</td><td>0</td><td>1</td></t<>	Consumer in network	0.94	0.24	0	1
Obtained marijuana online 0.09 0.29 0 1 Obtained marijuana in person 0.35 0.48 0 Obtained cocaine online 0.03 0.16 0 Obtained cocaine in person 0.10 0.30 0 1 Obtained basuco online 0 0.03 0 1 Obtained basuco online 0 0.03 0 1 Obtained basuco through friends 0.02 0.14 0 1 Basuco 0.24 0.43 0 1 Medium risk 0.02 0.14 0 1 Medium risk 0.02 0.14 0 1	Drug purchase sources indicators				
Obtained marijuana in person 0.35 0.48 0 1 Obtained marijuana through friends 0.60 0.49 0 1 Obtained cocaine online 0.03 0.16 0 1 Obtained cocaine in person 0.10 0.30 0 1 Obtained basuco online 0 0.03 0.18 0 1 Obtained basuco through friends 0.02 0.14 0 1 Obtained basuco through friends 0.02 0.14 0 1 Obtained basuco through friends 0.02 0.14 0 1 Offering indicators 0.24 0.43 0 1 Marijuana 0.02 0.14 0 1 Medium risk 0.05 0.22 0 1 Medium risk 0.05 0.22 0 1 Marijuana 10.8 9.80 0 50 Cocaine 3.67 7.78 0 47 Basuco 1.44 6.12 <	Obtained marijuana online	0.09	0.29	0	1
Obtained marijuana through friends 0.60 0.49 0 1 Obtained cocaine online 0.03 0.16 0 1 Obtained cocaine in person 0.10 0.30 0 1 Obtained basuco online 0 0.03 0 1 Obtained basuco in person 0.03 0.14 0 1 Obtained basuco through friends 0.02 0.14 0 1 Offering indicators 0.24 0.43 0 1 Basuco 0.24 0.43 0 1 Risk perception indicators U V 1 Low risk 0.02 0.14 0 1 Medium risk 0.05 0.22 0 1 Medium risk 0.02 0.14 0 1 Medium risk 0.02 0.14 0 1 Marijuana 0.02 0.14 0 1 Marijuana <td>Obtained marijuana in person</td> <td>0.35</td> <td>0.48</td> <td>0</td> <td>1</td>	Obtained marijuana in person	0.35	0.48	0	1
Obtained cocaine online 0.03 0.16 0 1 Obtained cocaine in person 0.10 0.30 0 1 Obtained cocaine through friends 0.10 0.30 0 1 Obtained basuco nine 0 0.03 0 1 Obtained basuco nine 0 0.03 0 1 Offering indicators 0 0.31 0 1 Marijuana 0.89 0.31 0 1 Cocaine 0.58 0.49 0 1 Basuco 0.22 0.14 0 1 Marijuana 0.89 0.31 0 1 Expencitor indicators 0.02 0.14 0 1 Medium risk 0.05 0.22 0 1 High risk 0.05 0.22 0 1 Marijuana 10.8 9.80 0 50 Cocaine 3.67 7.78 0 47 Basuco	Obtained marijuana through friends	0.60	0.49	0	1
Obtained cocaine in person 0.10 0.30 0 1 Obtained cocaine through friends 0.10 0.30 0 1 Obtained basuco nine 0 0.03 0 1 Obtained basuco niperson 0.03 0.18 0 1 Obtained basuco through friends 0.02 0.14 0 1 Offering indicators 0.89 0.31 0 1 Basuco 0.24 0.43 0 1 Basuco 0.24 0.43 0 1 Medium risk 0.05 0.22 0 1 High risk 0.93 0.26 0 1 Marijuana 0.65 0.22 0 1 Marijuana 10.8 9.80 50 50 Cocaine 3.67 7.78 0 47 Basuco 1.44 6.12 0 1 Parents and other demographic	Obtained cocaine online	0.03	0.16	0	1
Obtained cocaine through friends 0.10 0.30 0 1 Obtained basuco online 0 0.03 0 1 Obtained basuco in person 0.03 0.14 0 1 Obtained basuco through friends 0.02 0.14 0 1 Offering indicators 0 0.33 0 1 Marijuana 0.89 0.31 0 1 Cocaine 0.58 0.49 0 1 Basuco 0.24 0.43 0 1 Medium risk 0.02 0.14 0 1 Medium risk 0.05 0.22 0 1 High risk 0.05 0.22 0 1 Marijuana 10.8 9.80 0 50 Cocaine 3.67 7.78 0 47 Basuco 1.44 6.12 0 45 General and other demographics 0.25 0.43 0 1 Expenditure in drugs (monthly, 2019 USD) 30.73 58.24 0.26 488.70	Obtained cocaine in person	0.10	0.30	0	1
Obtained basuco online 0 0 1 Obtained basuco in person 0.03 0.18 0 1 Offering indicators 0.02 0.14 0 1 Offering indicators 0.89 0.31 0 1 Cocaine 0.58 0.49 0 1 Basuco 0.24 0.43 0 1 Risk perception indicators U U 1 Low risk 0.02 0.14 0 1 Medium risk 0.05 0.22 0 1 Medium risk 0.05 0.22 0 1 Marijuana 0.89 0.30 0.6 0 1 Marijuana 10.8 9.80 0 50 Cocaine 3.67 7.78 0 47 Basuco 1.44 6.12 0 45 General and other demographics Expenditure in drugs (monthly, 2019 USD	Obtained cocaine through friends	0.10	0.30	Ő	1
Obtained basico in person0.030.01801Obtained basico in person0.020.1401Offering indicators 0.02 0.1401Marijuana0.890.3101Cocaine0.580.4901Basuco0.240.4301Risk perception indicators 0.02 0.1401Low risk0.050.2201Marijuana0.050.2201Time consuming drugs (years) 0.65 0.2201Marijuana10.89.80050Cocaine3.677.78047Basuco1.446.12045General and other demographics 0.25 0.4301Parents at home0.150.3601Years of education12.213.79024Head of household0.390.4901Age (years)28.810.431365Metropolitan area0.370.4801Medicinal marijuana products0.570.4901Low SES0.570.4901Medium SES0.370.4801Medium SES0.370.4801Health indicators 0.57 0.4901Cocaine entral health0.690.4601Cocaine entral health <td>Obtained basuco online</td> <td>0.10</td> <td>0.03</td> <td>Ő</td> <td>1</td>	Obtained basuco online	0.10	0.03	Ő	1
Obtained basico through friends 0.02 0.14 0 1 Offering indicators 0.02 0.14 0 1 Marijuana 0.89 0.31 0 1 Cocaine 0.58 0.49 0 1 Basuco 0.24 0.43 0 1 Risk perception indicators 0.22 0.44 0 1 Marijuana 0.02 0.14 0 1 Medium risk 0.02 0.14 0 1 Marijuana 0.02 0.14 0 1 Marijuana 10.8 9.80 0 50 Cocaine 3.67 7.78 0 47 Basuco 1.44 61.2 0 45 General and other demographics 225 0.43 0 1 Parents at home 0.15 0.36 0 1 Vears of education 12.21	Obtained basuco in person	0.03	0.18	Ő	1
Othering indicators 0.02 0.14 0 1 Marijuana 0.89 0.31 0 1 Basuco 0.24 0.43 0 1 Basuco 0.24 0.43 0 1 Risk perception indicators 0.24 0.43 0 1 Low risk 0.05 0.22 0 1 Medium risk 0.05 0.22 0 1 High risk 0.05 0.22 0 1 Marijuana 10.8 9.80 0 50 Cocaine 3.67 7.78 0 47 Basuco 1.44 6.12 0 45 General and other demographics E E P and ther demographics 0.25 0.43 0 1 Parents at home 0.15 0.36 0 1 9 1 Vears of education 12.21 3.79 0 24 $46a$ 0 1 $36c$ 9	Obtained basuco through friends	0.00	0.10	0	1
Marijuana 0.89 0.31 0 1 Cocaine 0.58 0.49 0 1 Basuco 0.24 0.43 0 1 Risk perception indicators 1 1 Low risk 0.02 0.14 0 1 Medium risk 0.02 0.14 0 1 High risk 0.93 0.26 0 1 Time consuming drugs (years) 10.8 9.80 0 50 Marijuana 10.8 9.80 0 50 Cocaine 3.67 7.8 0 47 Basuco 1.44 6.12 0 45 General and other demographics 1 47 Expenditure in drugs (monthly, 2019 USD) 30.73 58.24 0.26 488.70 Female 0.25 0.43 0 1 Years of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medium SES 0.37 0.48 0 1 Head ohol consumption 0.85 0.36 0 1 Medium SES 0.37 0.48 0 1 Hedium SES 0.37 0.48 0 1 Hedium SES 0.37 0.48 0 1 Health indicators 0.60 0.23 0 1 <td< td=""><td>Offering indicators</td><td>0.02</td><td>0.14</td><td>0</td><td>1</td></td<>	Offering indicators	0.02	0.14	0	1
Mariyuani 0.03 0.03 0.04 0 1 Basuco 0.24 0.43 0 1 Basuco 0.24 0.43 0 1 Risk perception indicators 1 0.24 0.43 0 Low risk 0.02 0.14 0 1 Medium risk 0.05 0.22 0 1 Time consuming drugs (years) 0.33 0.26 0 1 Marijuana 10.8 9.80 0 50 Cocaine 3.67 7.78 0 47 Basuco 1.44 61.2 0 45 General and other demographics U U 0.55 0.43 0 Expenditure in drugs (monthly, 2019 USD) 30.73 58.24 0.26 488.70 Female 0.25 0.43 0 1 Years of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Metropolitan area 0.37 0.48 0 1 Medium SES 0.37 0.48 0 1 Hedi m SES 0.37 0.48 0 1 Hedi migiuana products 0.37 0.48 0 1 Good physical health 0.78 0.41 0 1 Hedium SES 0.37 0.48 0 1 Hedium SES 0.37 0.48 0 1 <t< td=""><td>Marijuana</td><td>0.89</td><td>0.31</td><td>0</td><td>1</td></t<>	Marijuana	0.89	0.31	0	1
Coordination 0.30 0.43 0 1 Basuco 0.24 0.43 0 1 Risk perception indicators 1 Low risk 0.02 0.14 0 1 Medium risk 0.05 0.22 0 1 High risk 0.93 0.02 0.14 0 1 Marijuana 0.03 0.02 0.14 0 1 Time consuming drugs (years) $Marijuana$ 10.8 9.80 0 50 Cocaine 3.67 7.78 0 47 Basuco 1.44 6.12 0 45 General and other demographics E Expenditure in drugs (monthly, 2019 USD) 30.73 58.24 0.26 488.70 Female 0.15 0.36 0 1 Parents at home 0.15 0.36 0 1 Vears of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Medicinal marijuana products 0.37 0.48 0 1 Medicinal marijuana products 0.37 0.49 0 1 Socioeconomic status (SES) indicators U U U 1 Idod mental health 0.69 0.46 0 1 Medicimal health 0.69 0.46 0 1 Idod mental health 0.69 0.46 0 1 <t< td=""><td>Coceine</td><td>0.85</td><td>0.31</td><td>0</td><td>1</td></t<>	Coceine	0.85	0.31	0	1
Dashed 0.44 0.45 0 1 Risk perception indicatorsLow risk 0.02 0.14 0 1 Medium risk 0.05 0.22 0 1 High risk 0.93 0.26 0 1 Time consuming drugs (years)Marijuana 10.8 9.80 0 50 Cocaine 3.67 7.78 0 47 Basuco 1.44 6.12 0 45 General and other demographicsExpenditure in drugs (monthly, 2019 USD) 30.73 58.24 0.26 488.70 Female 0.15 0.36 0 1 Parents at home 0.15 0.36 0 1 Vears of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.37 0.48 0 1 Socioeconomic status (SES) indicators U U 1 Low SES 0.57 0.49 0 1 Medium SES 0.37 0.48 0 1 Health indicators U U U 1 Good physical health 0.78 0.41 0 1 Good mental health 0.69 0.46 0 1 Health indicators	Baguag	0.00	0.43	0	1
Ruse perception indicatorsLow risk 0.02 0.14 0 1 Medium risk 0.05 0.22 0 1 High risk 0.93 0.26 0 1 Time consuming drugs (years) $Marijuana$ 10.8 9.80 0 50 Cocaine 3.67 7.78 0 47 Basuco 1.44 6.12 0 45 General and other demographicsExpenditure in drugs (monthly, 2019 USD) 30.73 58.24 0.26 488.70 Female 0.25 0.43 0 1 Parents at home 0.15 0.36 0 1 Years of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.39 0.49 0 1 Cogarette and alcohol consumption 0.85 0.36 0 1 Scioeconomic status (SES) indicatorsLow SES 0.37 0.48 0 1 Health indicators U U U 1 Good physical health 0.78 0.41 0 1 Good mental health 0.69 0.46 0 1 Health indicators U U U U U Drug dealers captures in	Bisk population indicators	0.24	0.45	0	1
Low risk 0.02 0.14 0 1 Medium risk 0.05 0.22 0 1 High risk 0.93 0.26 0 1 Time consuming drugs (years) 10.8 9.80 0 50 Cocaine 3.67 7.78 0 47 Basuco 1.44 6.12 0 45 General and other demographics 2 0.43 0 1 Expenditure in drugs (monthly, 2019 USD) 30.73 58.24 0.26 488.70 Female 0.25 0.43 0 1 Parents at home 0.15 0.36 0 1 Years of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medium SES 0.37 0.48 0 1 Medium SES 0.37 0.48 0 1 Health indicators U U U 1 Good physical health 0.78 0.41 0 1 Geographically distance-weighted instruments U U 0.69 0.46 0 1 Health indicators U U 0.78 0.52 0.15 3.05 Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05	Low risk	0.02	0.14	0	1
Medulin risk 0.03 0.22 0 1 High risk 0.93 0.26 0 1 Time consuming drugs (years) 10.8 9.80 0 50 Marijuana 10.8 9.80 0 50 Cocaine 3.67 7.78 0 47 Basuco 1.44 6.12 0 45 General and other demographics 2 0.43 0 1 Expenditure in drugs (monthly, 2019 USD) 30.73 58.24 0.26 488.70 Female 0.25 0.43 0 1 Parents at home 0.15 0.36 0 1 Years of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.39 0.49 0 1 Socioeconomic status (SES) indicators U U U 1 Low SES 0.37 0.48 0 1 Health indicators U U 1 0 1 Good physical health 0.78 0.41 0 1 Good physical health 0.69 0.46 0 1 Height indicators U U U U U Drug dealers captures in neighborhood (2018)<	LOW IISK	0.02	0.14	0	1
Inign Fisk 0.93 0.26 0 1 Time consuming drugs (years) 10.8 9.80 0 50 Marijuana 10.8 9.80 0 50 Cocaine 3.67 7.78 0 47 Basuco 1.44 6.12 0 45 General and other demographics U U 0 1 Expenditure in drugs (monthly, 2019 USD) 30.73 58.24 0.26 488.70 Female 0.25 0.43 0 1 Parents at home 0.15 0.36 0 1 Years of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.39 0.49 0 1 Cigarette and alcohol consumption 0.85 0.36 0 1 Socioeconomic status (SES) indicators U U I Low SES 0.37 0.48 0 1 Health indicators U U I I Good physical health 0.78 0.41 0 1 Good mental health 0.69 0.69 0.60 1 Good mental health 0.69 0.78 0.41 0 1 Good mental health 0.69 <	Medium risk	0.00	0.22	0	1
Marijuana 10.8 9.80 0 50 Cocaine 3.67 7.78 0 47 Basuco 1.44 6.12 0 45 General and other demographics Expenditure in drugs (monthly, 2019 USD) 30.73 58.24 0.26 488.70 Female 0.25 0.43 0 1 Parents at home 0.15 0.36 0 1 Years of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.39 0.49 0 1 Socioeconomic status (SES) indicators 0.37 0.48 0 1 Medium SES 0.37 0.48 0 1 1 Medium SES 0.37 0.48 0 1 1 Good physical health 0.69 <td>High risk</td> <td>0.93</td> <td>0.20</td> <td>0</td> <td>1</td>	High risk	0.93	0.20	0	1
Marijuana10.89.80050Cocaine 3.67 7.78 047Basuco 1.44 6.12 045General and other demographics $Expenditure in drugs (monthly, 2019 USD)$ 30.73 58.24 0.26 488.70 Female 0.25 0.43 01Parents at home 0.15 0.36 01Years of education 12.21 3.79 024Head of household 0.39 0.49 01Working 0.60 0.49 01Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 01Medicinal marijuana products 0.39 0.49 01Socioeconomic status (SES) indicators U U U U Low SES 0.57 0.49 01Medium SES 0.37 0.48 01Health indicators U U U U Good physical health 0.78 0.41 01Good mental health 0.69 0.46 01Geographically distance-weighted instruments U U U U Drug dealers captures in neighborhood (2018) 481.67 659.76 0 $3,587$ Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05	Multine consuming drugs (years)	10.0	0.00	0	50
Cocame 3.67 1.78 0 47 Basuco 1.44 6.12 0 45 General and other demographics $Expenditure in drugs (monthly, 2019 USD)$ 30.73 58.24 0.26 488.70 Female 0.25 0.43 0 1 Parents at home 0.15 0.36 0 1 Years of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.39 0.49 0 1 Socioeconomic status (SES) indicators U U U U Low SES 0.57 0.49 0 1 Medium SES 0.37 0.48 0 1 Health indicators U U U U Good physical health 0.78 0.41 0 1 Good mental health 0.78 0.41 0 1 Good mental health 0.78 0.52 0.15 3.05 Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05	Marijuana	10.8	9.80	0	50 47
Basuco 1.44 6.12 0 45 General and other demographicsExpenditure in drugs (monthly, 2019 USD) 30.73 58.24 0.26 488.70 Female 0.25 0.43 0 1 Parents at home 0.15 0.36 0 1 Years of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.39 0.49 0 1 Cigarette and alcohol consumption 0.85 0.36 0 1 Socioeconomic status (SES) indicators U U 1 1 Low SES 0.57 0.49 0 1 Heigh SES 0.06 0.23 0 1 Health indicators U U 1 0 Good physical health 0.69 0.46 0 1 Geographically distance-weighted instruments U U U 0 Drug dealers captures in neighborhood (2018) 481.67 659.76 0 $3,587$ Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05	Cocaine	3.67	7.78	0	47
General and other demographicsExpenditure in drugs (monthly, 2019 USD) 30.73 58.24 0.26 488.70 Female 0.25 0.43 0 1 Parents at home 0.15 0.36 0 1 Years of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.39 0.49 0 1 Cigarette and alcohol consumption 0.85 0.36 0 1 Socioeconomic status (SES) indicators U U U U Low SES 0.57 0.49 0 1 Heidium SES 0.37 0.48 0 1 Heidium SES 0.06 0.23 0 1 Health indicators U U U U Good physical health 0.69 0.46 0 1 Geographically distance-weighted instruments U U U U Drug dealers captures in neighborhood (2018) 481.67 659.76 0 $3,587$ Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05	Basuco	1.44	6.12	0	45
Expenditure in drugs (monthly, 2019 USD) 30.73 58.24 0.26 488.70 Female 0.25 0.43 0 1 Parents at home 0.15 0.36 0 1 Years of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.39 0.49 0 1 Cigarette and alcohol consumption 0.85 0.36 0 1 Socioeconomic status (SES) indicators 1 1 1 1 Low SES 0.57 0.49 0 1 1 Heidium SES 0.06 0.23 0 1 1 Heidium SES 0.06 0.23 0 1 1 Good physical health 0.69 0.46 0 1 1 Good mental health 0.69 0.46 0 1 1 Geographically distance-weighted instruments U U U U U U Drug dealers captures in neighborhood (2018) 481.67 659.76 0 $3,587$ Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05	General and other demographics	ao - a	50.04	0.00	100 -
Female 0.25 0.43 0 1 Parents at home 0.15 0.36 0 1 Years of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.39 0.49 0 1 Cigarette and alcohol consumption 0.85 0.36 0 1 Socioeconomic status (SES) indicators U U U U Low SES 0.57 0.49 0 1 Heidium SES 0.06 0.23 0 1 Health indicators U U U 1 Good physical health 0.78 0.41 0 1 Geographically distance-weighted instruments U U U U Drug dealers captures in neighborhood (2018) 481.67 659.76 0 3.587 Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05	Expenditure in drugs (monthly, 2019 USD)	30.73	58.24	0.26	488.70
Parents at home 0.15 0.36 0 1 Years of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.39 0.49 0 1 Cigarette and alcohol consumption 0.85 0.36 0 1 Socioeconomic status (SES) indicators 1 1 1 Low SES 0.57 0.49 0 1 Medium SES 0.37 0.48 0 1 High SES 0.06 0.23 0 1 Good physical health 0.78 0.41 0 1 Good mental health 0.69 0.46 0 1 Drug dealers captures in neighborhood (2018) 481.67 659.76 0 $3,587$ Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05	Female	0.25	0.43	0	1
Years of education 12.21 3.79 0 24 Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.39 0.49 0 1 Cigarette and alcohol consumption 0.85 0.36 0 1 Socioeconomic status (SES) indicatorsLow SES 0.57 0.49 0 1 Medium SES 0.37 0.48 0 1 High SES 0.06 0.23 0 1 Health indicators 0.69 0.46 0 1 Good physical health 0.69 0.46 0 1 Geographically distance-weighted instruments 0.78 0.41 0 1 Drug dealers captures in neighborhood (2018) 481.67 659.76 0 $3,587$ Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05	Parents at home	0.15	0.36	0	1
Head of household 0.39 0.49 0 1 Working 0.60 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.39 0.49 0 1 Cigarette and alcohol consumption 0.85 0.36 0 1 Socioeconomic status (SES) indicatorsLow SES 0.57 0.49 0 1 Medium SES 0.37 0.48 0 1 High SES 0.06 0.23 0 1 Health indicators 0.69 0.46 0 1 Good physical health 0.78 0.41 0 1 Good mental health 0.69 0.46 0 1 Drug dealers captures in neighborhood (2018) 481.67 659.76 0 $3,587$ Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05	Years of education	12.21	3.79	0	24
Working 0.60 0.49 0 1 Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.37 0.48 0 1 Cigarette and alcohol consumption 0.85 0.36 0 1 Socioeconomic status (SES) indicatorsLow SES 0.57 0.49 0 1 Medium SES 0.37 0.48 0 1 High SES 0.06 0.23 0 1 Health indicators 0.66 0.23 0 1 Good physical health 0.78 0.41 0 1 Good mental health 0.69 0.46 0 1 Geographically distance-weighted instruments 0.78 0.41 0 3.587 Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05 Ellicited cocaine price (2019 USD) 2.94 1.45 0.76 9.16	Head of household	0.39	0.49	0	1
Age (years) 28.8 10.43 13 65 Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.39 0.49 0 1 Cigarette and alcohol consumption 0.85 0.36 0 1 Socioeconomic status (SES) indicatorsLow SES 0.57 0.49 0 1 Medium SES 0.37 0.48 0 1 High SES 0.06 0.23 0 1 Health indicators 0.66 0.23 0 1 Good physical health 0.78 0.41 0 1 Good mental health 0.69 0.46 0 1 Drug dealers captures in neighborhood (2018) 481.67 659.76 0 $3,587$ Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05 Ellicited cocaine price (2019 USD) 2.94 1.45 0.76 9.16	Working	0.60	0.49	0	1
Metropolitan area 0.37 0.48 0 1 Medicinal marijuana products 0.39 0.49 0 1 Cigarette and alcohol consumption 0.85 0.36 0 1 Socioeconomic status (SES) indicatorsLow SES 0.57 0.49 0 1 Medium SES 0.37 0.48 0 1 High SES 0.06 0.23 0 1 Health indicators 0.66 0.23 0 1 Good physical health 0.78 0.41 0 1 Good mental health 0.69 0.46 0 1 Geographically distance-weighted instruments 0.78 0.41 0 3.587 Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05 Ellicited cocaine price (2019 USD) 2.94 1.45 0.76 9.16	Age (years)	28.8	10.43	13	65
Medicinal marijuana products 0.39 0.49 0 1 Cigarette and alcohol consumption 0.85 0.36 0 1 Socioeconomic status (SES) indicators 1 Low SES 0.57 0.49 0 1 Medium SES 0.37 0.48 0 1 High SES 0.06 0.23 0 1 Health indicators 0.78 0.41 0 1 Good physical health 0.78 0.41 0 1 Good mental health 0.69 0.46 0 1 Geographically distance-weighted instruments 0.78 0.52 0.576 0 Drug dealers captures in neighborhood (2018) 481.67 659.76 0 3.587 Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05 Ellicited cocaine price (2019 USD) 2.94 1.45 0.76 9.16	Metropolitan area	0.37	0.48	0	1
Cigarette and alcohol consumption 0.85 0.36 0 1 Socioeconomic status (SES) indicators 1 Low SES 0.57 0.49 0 1 Medium SES 0.37 0.48 0 1 High SES 0.06 0.23 0 1 Health indicators 0.66 0.23 0 1 Good physical health 0.78 0.41 0 1 Good mental health 0.69 0.46 0 1 Geographically distance-weighted instruments 0.29 0.46 0 1 Drug dealers captures in neighborhood (2018) 481.67 659.76 0 3.587 Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05 Ellicited cocaine price (2019 USD) 2.94 1.45 0.76 9.16	Medicinal marijuana products	0.39	0.49	0	1
Socioeconomic status (SES) indicatorsLow SES 0.57 0.49 0 1 Medium SES 0.37 0.48 0 1 High SES 0.06 0.23 0 1 Health indicators 0.78 0.41 0 1 Good physical health 0.69 0.46 0 1 Good mental health 0.69 0.46 0 1 Geographically distance-weighted instruments 0.78 0.52 0.587 Drug dealers captures in neighborhood (2018) 481.67 659.76 0 $3,587$ Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05 Ellicited cocaine price (2019 USD) 2.94 1.45 0.76 9.16	Cigarette and alcohol consumption	0.85	0.36	0	1
Low SES 0.57 0.49 0 1 Medium SES 0.37 0.48 0 1 High SES 0.06 0.23 0 1 Health indicators 0.78 0.41 0 1 Good physical health 0.69 0.46 0 1 Good mental health 0.69 0.46 0 1 Geographically distance-weighted instruments 0.78 0.52 0.587 Drug dealers captures in neighborhood (2018) 481.67 659.76 0 3.587 Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05 Ellicited cocaine price (2019 USD) 2.94 1.45 0.76 9.16	Socioeconomic status (SES) indicators				
Medium SES 0.37 0.48 0 1 High SES 0.06 0.23 0 1 Health indicators 0.69 0.41 0 1 Good physical health 0.78 0.41 0 1 Good mental health 0.69 0.46 0 1 Geographically distance-weighted instrumentsDrug dealers captures in neighborhood (2018) 481.67 659.76 0 3.587 Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05 Ellicited cocaine price (2019 USD) 2.94 1.45 0.76 9.16	Low SES	0.57	0.49	0	1
High SES 0.06 0.23 0 1 Health indicators 0.06 0.23 0 1 Good physical health 0.78 0.41 0 1 Good mental health 0.69 0.46 0 1 Geographically distance-weighted instruments 0.78 0.59.76 0 3,587 Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05 Ellicited cocaine price (2019 USD) 2.94 1.45 0.76 9.16	Medium SES	0.37	0.48	0	1
Health indicators 0.78 0.41 0 1 Good physical health 0.69 0.46 0 1 Good mental health 0.69 0.46 0 1 Geographically distance-weighted instruments 0 1 0 1 Drug dealers captures in neighborhood (2018) 481.67 659.76 0 3,587 Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05 Ellicited cocaine price (2019 USD) 2.94 1.45 0.76 9.16	High SES	0.06	0.23	0	1
Good physical health 0.78 0.41 0 1 Good mental health 0.69 0.46 0 1 Geographically distance-weighted instruments Units 0 1 0 1 Drug dealers captures in neighborhood (2018) 481.67 659.76 0 3,587 Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05 Ellicited cocaine price (2019 USD) 2.94 1.45 0.76 9.16	Health indicators				
Good mental health 0.69 0.46 0 1 Geographically distance-weighted instruments 0 0 1 1 <th1< th=""> <th1< th=""> <th1< th=""> <th1< t<="" td=""><td>Good physical health</td><td>0.78</td><td>0.41</td><td>0</td><td>1</td></th1<></th1<></th1<></th1<>	Good physical health	0.78	0.41	0	1
Geographically distance-weighted instruments Drug dealers captures in neighborhood (2018) 481.67 659.76 0 3,587 Ellicited marijuana price (2019 USD) 0.78 0.52 0.15 3.05 Ellicited cocaine price (2019 USD) 2.94 1.45 0.76 9.16	Good mental health	0.69	0.46	0	1
Drug dealers captures in neighborhood (2018)481.67659.7603,587Ellicited marijuana price (2019 USD)0.780.520.153.05Ellicited cocaine price (2019 USD)2.941.450.769.16	Geographically distance-weighted instruments				
Ellicited marijuana price (2019 USD)0.780.520.153.05Ellicited cocaine price (2019 USD)2.941.450.769.16	Drug dealers captures in neighborhood (2018)	481.67	659.76	0	$3,\!587$
Ellicited cocaine price (2019 USD) 2.94 1.45 0.76 9.16	Ellicited marijuana price (2019 USD)	0.78	0.52	0.15	3.05
	Ellicited cocaine price (2019 USD)	2.94	1.45	0.76	9.16

Table 2: Descriptive statistics: Individual characteristics

Notes: Total sample size includes 1236 consumers from ENCSPA survey in Colombia. The representative (modal) drug user has drug dealers in his neighborhood, lives in a low-socioeconomic stratum, his friends also use drugs, consumes alcohol and cigarettes, he is 29 years-old, studied 12 years, and works. This person spends on average USD 30.7 per month in drugs, and has access to marijuana, cocaine and basuco. He seems to have a high risk perception about drugs. This person has used marijuana per 11 years, and reports to have a good physical and mental health.

where individuals in their thirties have the largest average consumption (see left panel of Figure 3), it seems that the market composition is explained by the largest amount of users is in their twenties (see Figure 2).

2.3 Descriptive patterns of prices and consumption

Legalization of marijuana in different countries has resulted in notable price changes. For instance, in Canada, prices increased by 32% post-legalization due to taxes and regulatory duties, whereas in Uruguay, prices decreased due to a 0% taxation policy aimed at undercutting the illegal market. In the specific case of Colombia, the production cost of one gram of marijuana is approximately US¢1, while the average street price is around US¢83. This significant illegality margin could diminish under legalization, leading to price adjustments that may alter the consumption behavior of current regular users. These changes are not limited to marijuana but could also affect the demand for cocaine and basuco due to potential complementary or substitution patterns in drug use. We first provide an exploration into descriptive results based on the associations between price, income and eventual consumption.

Figure 5: Consumption vs price



Notes: Logarithm of consumption versus logarithm of price: Marijuana, cocaine and basuco are in panels A (left), B (middle) and C (right), respectively. There is a negative association between drug consumption and prices.

Figure 5 presents scatter plots of the logarithm of monthly consumption for marijuana (left panel, A), cocaine (middle panel, B), and basuco (right panel, C) against their corresponding log prices. The plots reveal negative associations between monthly consumption and price. Specifically, the unconditional price elasticities are estimated at -0.09 (0.01), -0.16 (0.03), and -0.06 (0.05) for marijuana, cocaine, and basuco, respectively (standard errors in parentheses), suggesting that the demand for these drugs is inelastic. This implies that a potential price reduction would lead to a less than proportional increase in consumption, ultimately resulting in a revenue decrease for drug dealers, aside from the additional competition from legal

marijuana. However, it is important to emphasize that this is a preliminary analysis that does not account for additional covariates or address potential endogeneity concerns.

Finally, we note that most parametric demand systems such as the AID or QAID place a restriction on the rank of the Engel curves (relationship between expenditure and consumption) such that only quadratic relationships can be modelled using these demand systems. This is not the case for the EASI demand system as it can deal with arbitrarily large rank of the Engel curves. While this is a less restrictive assumption when studying the demand for more standard goods, the demand for illicit drugs presents non-linearities that go above the simple quadratic patterns in Engel curves that other demand systems can reproduce. As shown in Figure 6, a non-parametric estimate of these Engel curves and their slopes using our full sample of consumers showcases highly non-linear patterns for drug consumption, which require flexible demand systems such as the EASI to be captured accurately.

3 Econometric framework

The EASI demand system (Lewbel and Pendakur, 2009) is constructed to satisfy the standard microeconomic restrictions on demand functions. Specifically, this system satisfies the axioms of choice, such that additivity, homogeneity, and symmetry restrictions are easily imposed to perform estimation. Moreover, the rank in the function space spanned by the Engel curves can be more than three, such that the Engel curves may take flexible shapes as those found in granular demand data. This is a feature that is not shared by two of the most used demand systems in the literature: the almost ideal demand system (AID; Deaton and Muellbauer, 1980) or quadratic AID (QAID; Banks et al., 1997). These properties are particularly relevant in our case as we work with micro-level data where the variation in expenditure is not smoothed out by aggregation (Blundell et al., 2007, Zhen et al., 2014).

3.1 Review: The EASI model

Details of the EASI demand system can be found in Lewbel and Pendakur (2009). We outline the basic framework here for convenience of exposition. In our application, we simultaneously model S = 3 implicit Marshallian budget shares, given by $\boldsymbol{\omega}(\tilde{\boldsymbol{p}}_i, y_i, \boldsymbol{h}_i, \tilde{\boldsymbol{\varepsilon}}_i) \coloneqq \tilde{\boldsymbol{w}}_i = [\text{marijuana}_i, \text{cocaine}_i, \text{basuco}_i]^{\top}$ for individuals $i = 1, 2, \ldots, n$, where

$$\widetilde{\boldsymbol{w}}_{i} = \sum_{r=0}^{R} \widetilde{\boldsymbol{b}}_{r} y_{i}^{r} + \widetilde{\boldsymbol{A}}_{0} \widetilde{\boldsymbol{p}}_{i} + \sum_{m=1}^{M_{p}} \widetilde{\boldsymbol{A}}_{m} \widetilde{\boldsymbol{p}}_{i} h_{im}^{p} + \widetilde{\boldsymbol{B}} \widetilde{\boldsymbol{p}}_{i} y_{i} + \widetilde{\boldsymbol{C}} \boldsymbol{h}_{i} + \widetilde{\boldsymbol{D}} \boldsymbol{h}_{i}^{y} y_{i} + \widetilde{\boldsymbol{\varepsilon}}_{i},$$
(1)

$$y_i = \frac{e_i - \widetilde{\boldsymbol{p}}_i^\top \widetilde{\boldsymbol{w}}_i - \sum_{m=0}^M \widetilde{\boldsymbol{p}}_i^\top \widetilde{\boldsymbol{A}}_m \widetilde{\boldsymbol{p}}_i h_{im}^p / 2}{1 - \widetilde{\boldsymbol{p}}_i^\top \widetilde{\boldsymbol{B}} \widetilde{\boldsymbol{p}}_i / 2}.$$
(2)

Implicit utility y_i is an exact affine transformation of the (log) Stone index given by $\tilde{p}_i^{\top} \tilde{w}_i$. Additionally, e_i denotes log-nominal expenditure, and \tilde{p}_i is the log-price vector faced by individual i.⁶ The system of equations in (1) can involve polynomials of arbitrary degree R in y, providing flexibility for the Engel curves, and can also take into account socioeconomic controls h_i (an M-dimensional vector, where $h_{i0} = 1$ is excluded from h_i).

The EASI model naturally allows for sources of *observable* heterogeneity through the inclusion of socioeco-

⁶We emphasize that our data allows us to obtain individual-specific price levels, which is not common in most demand applications where consumers face an aggregate measure of price.



Figure 6: Non-parametric Engel curves of demand for illicit drugs on full sample

Notes: Engel curves estimated using a local regression procedure (Cleveland et al., 2017). First derivative computed using simple sorted differences along a grid of expenditure values. Confidence intervals are point-wise 95% percentile-*t* intervals from 5,000 bootstrap replications. Full sample Engel curves exhibit clear non-linearities that are not captured by limited-rank demand systems (Lewbel and Pendakur, 2009).

nomic controls that interact with prices (\boldsymbol{h}_i^p) and implicit utility (\boldsymbol{h}_i^y) . Each of these vectors of controls, with dimensions M_p and M_y respectively, can contain distinct variables from one another and to \boldsymbol{h}_i , or could even be empty. The stochastic error $\tilde{\boldsymbol{\varepsilon}}_i$, on the other hand, can directly be interpreted as a source of unobserved preference heterogeneity. However, this heterogeneity does not affect the elasticities or Engel curves, as these objects depend on parameters and observable characteristics. Table 3 presents a complete depiction of all price and expenditure effects that can be derived from the EASI demand system.

To satisfy standard microeconomic regularity conditions in the EASI model, one can impose the following restrictions on the coefficients in system (1): $\tilde{A}_m \mathbf{1}_S = \tilde{B}\mathbf{1}_S = \mathbf{0}_S$ for cost function homogeneity; the unit-sum constraint of shares requires $\mathbf{1}_S^{\top} \tilde{b}_0 = 1$, $\mathbf{1}_S^{\top} \tilde{b}_r = 0$ for $r = 1, \ldots, R$, $\mathbf{1}_S^{\top} \tilde{A}_m = \mathbf{0}_S^{\top}$ for $m = 0, \ldots, M_p$, $\mathbf{1}_S^{\top} \tilde{B} = \mathbf{0}_S^{\top}$, $\mathbf{1}_S^{\top} \tilde{C} = \mathbf{0}_M^{\top}$, $\mathbf{1}_S^{\top} \tilde{D} = \mathbf{0}_{M_y}^{\top}$ and $\mathbf{1}_S^{\top} \tilde{\varepsilon}_i = 0$ for $i = 1, \ldots, n$; Slutsky symmetry requires all \tilde{A}_m matrices for $m = 0, \ldots, M_p$ and \tilde{B} to be symmetric; strict cost monotonicity requires $\tilde{p}^{\top} \left[\sum_{r=0}^R \tilde{b}_r r y^{r-1} + \tilde{D} h^y + \tilde{B} p/2 \right] + 1 > 0$; finally, a sufficient and necessary condition for concavity of the cost function is negative semi-definiteness of the normalized Slutsky matrix $\sum_{m=0}^{M_p} \tilde{A}_m h_m^p + \tilde{B} y + \tilde{w} \tilde{w}^{\top} - W$, where W is a diagonal matrix whose diagonal equals \tilde{w} , and $\mathbf{0}_S$ and $\mathbf{1}_S$ are S-dimensional vector of zeros and ones, respectively.

Table 3: Summary of price and income effects obtained from the EASI demand system

	TT 1 .	
Type	Hicksian	
Share price semi-elasticities	$ abla_{\widetilde{m{p}}}m{\omega}^*(\widetilde{m{p}},y,\widetilde{m{h}},\widetilde{m{e}})\coloneqq \Gamma = \sum_{m=0}^{M_p} \widetilde{m{A}}_m h_m^p + \widetilde{m{B}} y$	
Income share semi-elasticities	$ abla_y oldsymbol{\omega}^*(\widetilde{oldsymbol{p}},y,\widetilde{oldsymbol{h}},\widetilde{oldsymbol{e}}) = \sum_{r=1}^R \widetilde{oldsymbol{b}}_r r y^{r-1} + \widetilde{oldsymbol{D}} oldsymbol{h}^y + \widetilde{oldsymbol{B}} \widetilde{oldsymbol{p}}$	
Demand price elasticities	$\epsilon^{H}_{lj} \coloneqq -\mathbb{1}(l=j) + rac{1}{w_l} abla_{\widetilde{oldsymbol{p}}} oldsymbol{\omega}^*(\widetilde{oldsymbol{p}},y,oldsymbol{h},\widetilde{oldsymbol{arepsilon}})_{lj} + w_j$	
Normalized Slutsky matrix	$oldsymbol{S}\coloneqq oldsymbol{\Gamma}+\widetilde{oldsymbol{w}}\widetilde{oldsymbol{w}}^{ op}-oldsymbol{W}$	
Type	Marshallian	
Share price semi-elasticities	$\nabla_{\widetilde{\boldsymbol{p}}}\widetilde{\boldsymbol{w}}^*(\widetilde{\boldsymbol{p}},e,\boldsymbol{h},\widetilde{\boldsymbol{\varepsilon}}) = \nabla_{\widetilde{\boldsymbol{p}}}\boldsymbol{\omega}^*(\widetilde{\boldsymbol{p}},y,\boldsymbol{h},\widetilde{\boldsymbol{\varepsilon}}) - \nabla_e\widetilde{\boldsymbol{w}}^*(\widetilde{\boldsymbol{p}},e,\boldsymbol{h},\widetilde{\boldsymbol{\varepsilon}})\boldsymbol{\omega}^*(\widetilde{\boldsymbol{p}},\boldsymbol{h},y,\widetilde{\boldsymbol{\varepsilon}})^\top$	
Income share semi-elasticities	$\nabla_{e} \widetilde{\boldsymbol{w}}^{*}(\widetilde{\boldsymbol{p}}, e, \boldsymbol{h}, \widetilde{\boldsymbol{\varepsilon}}) = \left(\boldsymbol{I}_{J} + \frac{\nabla_{y} \boldsymbol{\omega}^{*}(\widetilde{\boldsymbol{p}}, \boldsymbol{h}, y, \widetilde{\boldsymbol{\varepsilon}}) \widetilde{\boldsymbol{p}}^{\top}}{1 - \widetilde{\boldsymbol{p}}^{\top} \widetilde{\boldsymbol{B}} \widetilde{\boldsymbol{p}}/2}\right)^{-1} \left(\frac{\nabla_{y} \boldsymbol{\omega}^{*}(\widetilde{\boldsymbol{p}}, \boldsymbol{h}, y, \widetilde{\boldsymbol{\varepsilon}})}{1 - \widetilde{\boldsymbol{p}}^{\top} \widetilde{\boldsymbol{B}} \widetilde{\boldsymbol{p}}/2}\right)$	
Demand price elasticities	$\widetilde{\boldsymbol{\varepsilon}}_{lj}^{M} \coloneqq -\mathbb{1}(l=j) + \frac{1}{w_l} \nabla_{\widetilde{\boldsymbol{p}}} \boldsymbol{\omega}^* (\widetilde{\boldsymbol{p}}, y, \boldsymbol{h}, \widetilde{\boldsymbol{\varepsilon}})_{lj} - \frac{w_j}{w_l} \nabla_e \widetilde{\boldsymbol{w}}^* (\widetilde{\boldsymbol{p}}, e, \boldsymbol{h}, \widetilde{\boldsymbol{\varepsilon}})_l$	
Demand income elasticities	$\eta_j^M \coloneqq rac{1}{w_j} abla_e \widetilde{oldsymbol{w}}^*(\widetilde{oldsymbol{p}}, e, oldsymbol{h}, \widetilde{oldsymbol{arepsilon}})_j + 1$	
Marshallian Engel curve	$\widetilde{m{w}}_i^* = \sum_{r=0}^R \widetilde{m{b}}_r e_i^r + \widetilde{m{C}}m{h}_i + \widetilde{m{D}}m{h}_i^y e_i + \widetilde{m{arepsilon}}_i$	
Notes: Price and income effects from exact affine Stone index (EASI) model (Lewbel and Pendakur		

Notes: Price and income effects from exact affine Stone index (EASI) model (Lewbel and Pendakur, 2009).

3.2 Model Specification

We begin by specifying the system of equations (1) in latent form using the last share (S) as the base category (numeraire good). These latent shares, denoted by $\widetilde{w}_i^* = [w_{i1}^*, \ldots, w_{iS}^*]^\top$, capture the un-normalized marginal utility of individual *i* of consuming each of the goods considered (illicit drugs in our case). We can then

recover observable shares w_i from latent ones as in Kasteridis et al. (2011) and Ramírez-Hassan (2021):

$$w_{il} = \begin{cases} \frac{w_{il}^*}{\sum_{j \in L_i} w_{ij}^*} & \text{if } w_{il}^* > 0, \\ 0 & \text{if } w_{il}^* \le 0, \end{cases} \quad \text{for } l = 1, \dots, S,$$
(3)

where $L_i = \{l : w_{il}^* > 0\} = \{l : w_{il} > 0\}$ is the set of goods with positive consumption for individual *i*. We *impose* the same microeconomic restrictions discussed previously and express the EASI demand system directly on latent shares as

$$\boldsymbol{w}_{i}^{*} = \sum_{r=0}^{R} \boldsymbol{b}_{r} y_{i}^{r} + \sum_{m=0}^{M_{p}} \boldsymbol{A}_{m} \boldsymbol{p}_{i} h_{im}^{p} + \boldsymbol{B} \boldsymbol{p}_{i} y_{i} + \boldsymbol{C} h_{i} + \boldsymbol{D} \boldsymbol{h}_{i}^{y} y_{i} + \boldsymbol{\varepsilon}_{i}, \qquad (4)$$

where these variables and coefficients are defined from the original quantities as

$$\begin{split} \widetilde{\boldsymbol{w}}_{i} &\coloneqq \begin{bmatrix} \boldsymbol{w}_{i} \\ \boldsymbol{w}_{iS} \end{bmatrix}, \quad \widetilde{\boldsymbol{w}}_{i}^{*} \coloneqq \begin{bmatrix} \boldsymbol{w}_{i}^{*} \\ \boldsymbol{w}_{iS}^{*} \end{bmatrix}, \quad \widetilde{\boldsymbol{\varepsilon}}_{i} \coloneqq \begin{bmatrix} \boldsymbol{\varepsilon}_{i} \\ \boldsymbol{\varepsilon}_{iS} \end{bmatrix}, \quad \boldsymbol{p}_{i} \coloneqq \begin{bmatrix} p_{i1} - p_{iS} \\ \vdots \\ p_{is} - p_{iS} \end{bmatrix}, \\ \widetilde{\boldsymbol{b}}_{r} &\coloneqq \begin{bmatrix} \boldsymbol{b}_{r} \\ \boldsymbol{b}_{rS} \end{bmatrix}, \text{ for } r = 0, \dots, R, \quad \widetilde{\boldsymbol{A}}_{m} \coloneqq \begin{bmatrix} \boldsymbol{A}_{m} & \boldsymbol{A}_{m,S1} \\ \boldsymbol{A}_{m,1S} & \boldsymbol{A}_{m,SS} \end{bmatrix}, \text{ for } m = 0, \dots, M_{p}, \\ \widetilde{\boldsymbol{B}}_{(S \times S)} &\coloneqq \begin{bmatrix} \boldsymbol{B} & \boldsymbol{B}_{S1} \\ \boldsymbol{B}_{1S} & \boldsymbol{B}_{SS} \end{bmatrix}, \quad \widetilde{\boldsymbol{C}}_{(S \times M)} \coloneqq \begin{bmatrix} \boldsymbol{C} \\ \boldsymbol{C}_{S}^{\top} \end{bmatrix}, \text{ and } \quad \widetilde{\boldsymbol{D}}_{S} \coloneqq \begin{bmatrix} \boldsymbol{D} \\ \boldsymbol{D}_{S}^{\top} \end{bmatrix}. \end{split}$$

Note that the unit-sum, cost function homogeneity, and Slutsky symmetry restrictions allow us to recover the share and coefficients from the base category in terms of the information from remaining goods. That is, once we impose these restrictions, we only need to model s := S - 1 of the shares. Here, \mathbf{p}_i represents the vector of relative log-prices with respect to the base price p_{iS} , and Slutsky symmetry also implies $\mathbf{A}_m = \mathbf{A}_m^{\top}$ for $m = 0, \ldots, M_p$ and $\mathbf{B} = \mathbf{B}^{\top}$.

Each equation in the reduced system (4) can be written as

$$w_{il}^* = \boldsymbol{x}_i^\top \boldsymbol{\beta}_l^{(1)} + \boldsymbol{p}_i^{*\top} \boldsymbol{\delta}_l + \varepsilon_{il} , \qquad (5)$$

where $\boldsymbol{x}_i \coloneqq [1, y_i, \dots, y_i^R, \boldsymbol{h}_i^{\top}, \boldsymbol{h}_i^{y^{\top}} y_i]^{\top}$ collects all exogenous variables in a vector of dimension $1+R+M+M_y$, $\boldsymbol{p}_i^* \coloneqq [\boldsymbol{p}_i^{\top} \boldsymbol{h}_{i0}^p, \dots, \boldsymbol{p}_i^{\top} \boldsymbol{h}_{iM_p}^p, \boldsymbol{p}_i^{\top} y_i]^{\top}$ collects all endogenous variables in a vector of dimension $s(M_p + 2)$, $\boldsymbol{\beta}_l^{(1)} \coloneqq [b_{0l}, \dots, b_{Rl}, \boldsymbol{C}_l^{\top}, \boldsymbol{D}_l^{\top}]^{\top}$, and $\boldsymbol{\delta}_l \coloneqq [\boldsymbol{A}_{0l}^{\top}, \dots, \boldsymbol{A}_{M_pl}^{\top}, \boldsymbol{B}_l^{\top}]^{\top}$. Stacking across the $l = 1, \dots, s$ equations yields some redundancy in $\boldsymbol{\delta} \coloneqq [\boldsymbol{\delta}_1^{\top}, \dots, \boldsymbol{\delta}_s^{\top}]^{\top}$ due to the Slutsky symmetry constraint. Let P_{s,M_p} be a $s^2(M_p + 2) \times s^2(M_p + 2)$ permutation matrix such that $\boldsymbol{\delta}^{\top} = [\operatorname{vec}(\boldsymbol{A}_0)^{\top}, \dots, \operatorname{vec}(\boldsymbol{A}_{M_p})^{\top}, \operatorname{vec}(\boldsymbol{B})^{\top}]\boldsymbol{P}_{s,M_p}^{\top}$ and \boldsymbol{D}_s be the $s^2 \times s(s+1)/2$ duplication matrix such that $\boldsymbol{D}_s \operatorname{vec}(\boldsymbol{A}) = \operatorname{vech}(\boldsymbol{A})$ for any symmetric $s \times s$ matrix \boldsymbol{A} . Define $\boldsymbol{X}_i \coloneqq \boldsymbol{I}_s \otimes \boldsymbol{X}_i^{\top}$ and

$$\begin{aligned} \boldsymbol{P}_{i}^{*} &\coloneqq (\boldsymbol{I}_{s} \otimes \boldsymbol{p}_{i}^{*\top}) \boldsymbol{P}_{s,M_{p}}(\boldsymbol{I}_{M_{p}+2} \otimes \boldsymbol{D}_{s}) \\ &= \left[(\boldsymbol{I}_{s} \otimes \boldsymbol{p}_{i}^{\top}) \boldsymbol{D}_{s} \quad (\boldsymbol{I}_{s} \otimes \boldsymbol{p}_{i}^{\top}) h_{i1}^{p} \boldsymbol{D}_{s} \quad \cdots \quad (\boldsymbol{I}_{s} \otimes \boldsymbol{p}_{i}^{\top}) h_{iM_{p}}^{p} \boldsymbol{D}_{s} \quad (\boldsymbol{I}_{s} \otimes \boldsymbol{p}_{i}^{\top}) y_{i} \boldsymbol{D}_{s} \right]. \end{aligned}$$

With these definitions at hand, we can stack across equations $l = 1, \ldots, s$ in (5) to obtain

$$\boldsymbol{w}_i^* = \boldsymbol{X}_i \boldsymbol{\beta}^{(1)} + \boldsymbol{P}_i^* \boldsymbol{\beta}^{(2)} + \boldsymbol{\varepsilon}_i \,, \tag{6}$$

where $\boldsymbol{\beta}^{(1)} \coloneqq [\boldsymbol{\beta}_1^{(1)\top}, \dots, \boldsymbol{\beta}_s^{(1)\top}]^\top$ and $\boldsymbol{\beta}^{(2)} \coloneqq [\operatorname{vech}(\boldsymbol{A}_0)^\top, \dots, \operatorname{vech}(\boldsymbol{A}_{M_p})^\top, \operatorname{vech}(\boldsymbol{B})^\top]^\top$. Additionally, we assume we have access to an ℓ -dimensional vector \boldsymbol{z}_i of excluded instruments that are uncorrelated with $\boldsymbol{\varepsilon}_i$ and are relevant to predict \boldsymbol{p}_i^* , and additionally we have access to enough instruments to satisfy $\ell \geq s(M_p+2)$ as a necessary condition for identification.⁷ We can finally express the system of latent variables and endogenous regressors as

$$\boldsymbol{w}_{i}^{*} = \boldsymbol{F}_{i}\boldsymbol{\beta} + \boldsymbol{\varepsilon}_{i}$$

$$\boldsymbol{p}_{i}^{*} = \boldsymbol{G}_{i}\boldsymbol{\gamma} + \boldsymbol{u}_{i},$$

$$(7)$$

where $\mathbf{F}_i \coloneqq [\mathbf{X}_i, \mathbf{P}_i^*], \mathbf{G}_i \coloneqq [\mathbf{I}_{s(M_p+2)} \otimes \mathbf{x}_i^\top, \mathbf{I}_{s(M_p+2)} \otimes \mathbf{z}_i^\top], \boldsymbol{\beta} \coloneqq [\boldsymbol{\beta}^{(1)\top}, \boldsymbol{\beta}^{(2)\top}]^\top$ is the structural coefficient of interest with dimension $d_{\boldsymbol{\beta}} \coloneqq s(1+R+M+M_y) + s(s+1)(M_p+2)/2$, and $\boldsymbol{\gamma}$ are the first-stage coefficients with dimension $d_{\boldsymbol{\gamma}} \coloneqq s(M_p+2)(1+R+M+M_y+\ell)$. To reproduce the endogeneity in the system, we allow for correlation between $\boldsymbol{\varepsilon}_i$ and \boldsymbol{u}_i through a multivariate normal distribution with non-diagonal covariance matrix $\boldsymbol{\Sigma}$.

To acknowledge further unobserved heterogeneity, we allow for individuals to differ according to unobserved types, where drug demand responses vary across types and are similar for all individuals of the same type. That is, we are assuming that our sample is representative of a population composed by sub-populations, with homogeneous drug preferences within each group and heterogeneity across them. Introduce an individual cluster indicator $\psi_i \in \{1, \ldots, J\}$ such that $\psi_i = j$ means the observation belongs to cluster C_j , for $j = 1, \ldots, J$. We will assume J, the number of clusters, to be known and experiment with its value in our applications.

As the structural coefficients capture the drug preferences of individuals, we allow for all elements in the structural equation (β and the relevant components of Σ) to vary at the cluster-level. However, we do not allow for the first-stage parameters (γ and Σ_{uu}) to vary with the clusters as it is unlikely that the same population segments driving heterogeneity in drug preferences also drive heterogeneity in the reduced form. Additionally, using cluster-specific first stage regressions do not allow the model to exploit the full variability in instruments to recover these coefficients, leading to artificial issues of weak instruments and larger uncertainty. We incorporate this into our model by assuming

$$\begin{bmatrix} \boldsymbol{\varepsilon}_i \\ \boldsymbol{u}_i \end{bmatrix} | \psi_i = j \stackrel{iid}{\sim} \mathcal{N}_{s(M_p+3)}(\boldsymbol{0}_{s(M_p+3)}, \boldsymbol{\Sigma}_j) \quad \text{with} \quad \boldsymbol{\Sigma}_j = \begin{bmatrix} \boldsymbol{\Sigma}_{j,\varepsilon\varepsilon} & \boldsymbol{\Sigma}_{j,\varepsilon u} \\ \boldsymbol{\Sigma}_{j,u\varepsilon} & \boldsymbol{\Sigma}_{uu} \end{bmatrix}$$
(8)

independently across individuals, where $\mathcal{N}(\cdot \mid \mu, \Sigma)$ represents the density function of a normally distributed variable with mean μ and variance Σ . Finally, we note that by also including priors for both the cluster indicators and assignment probabilities, their updated posterior produce a data-driven probabilistic assignment of individuals to clusters. This is an important policy tool, as we will see that our model meaningfully classifies individuals according to their drug-use behaviour and risk. Additionally, as we can correlate the characteristics of these individuals to the model's assignment, it also allows us to preemptively identify

⁷The endogenous \boldsymbol{p}_i^* is composed of prices \boldsymbol{p}_i and cross-products of \boldsymbol{p}_i with exogenous variables h_i and y_i . If we have l credible instruments for prices (denoted by $\tilde{\boldsymbol{z}}_i$) with $l \geq s$, then $\tilde{\boldsymbol{z}}_i h_{01}, \ldots, \tilde{\boldsymbol{z}}_i h_{iM_p}$, and $\tilde{\boldsymbol{z}}_i y_i$ are valid instruments as well as long as they contain sufficient variation across individuals.

individuals who are highly at-risk due to their drug use.

Putting it all together, this implies the likelihood

$$p(\boldsymbol{w}_{i}^{*},\boldsymbol{p}_{i}^{*} \mid \psi_{i}=j,\boldsymbol{\beta},\boldsymbol{\gamma},\boldsymbol{\Sigma}) \propto |\boldsymbol{\Sigma}_{j}|^{-\frac{1}{2}} \exp\left\{-\frac{1}{2} \begin{bmatrix} \boldsymbol{w}_{i}^{*}-\boldsymbol{F}_{i}\boldsymbol{\beta}_{j} \\ \boldsymbol{p}_{i}^{*}-\boldsymbol{G}_{i}\boldsymbol{\gamma} \end{bmatrix}^{\top} \begin{bmatrix} \boldsymbol{\Sigma}_{j,\varepsilon\varepsilon} & \boldsymbol{\Sigma}_{j,\varepsilon u} \\ \boldsymbol{\Sigma}_{j,u\varepsilon} & \boldsymbol{\Sigma}_{uu} \end{bmatrix}^{-1} \begin{bmatrix} \boldsymbol{w}_{i}^{*}-\boldsymbol{F}_{i}\boldsymbol{\beta}_{j} \\ \boldsymbol{p}_{i}^{*}-\boldsymbol{G}_{i}\boldsymbol{\gamma} \end{bmatrix}\right\}.$$
 (9)

Note that the right hand side of equation (9) is proportional to the density of a normal distribution on $(\boldsymbol{w}_i^*, \boldsymbol{p}_i^*)$ with mean $\mu_{ij} \coloneqq [(\boldsymbol{F}_i \boldsymbol{\beta}_j)^\top, (\boldsymbol{G}_i \boldsymbol{\gamma})^\top]^\top$ and covariance matrix $\boldsymbol{\Sigma}_j$. This normality does not formally hold since \boldsymbol{F}_i contains the endogenous \boldsymbol{p}_i^* and so the mean of this distribution would depend on the value of the random variable. However, the determinant of the Jacobian of the inverse transformation from $(\boldsymbol{\varepsilon}_i, \boldsymbol{u}_i)$ to $(\boldsymbol{w}_i^*, \boldsymbol{p}_i^*)$ is 1, such that we can use the normal representation for all our estimation purposes.

Additionally, we note how this unobserved clustering structure leads directly to a finite mixture approach. Let $\phi_j := \Pr(\psi_i = j)$ for all clusters $j = 1, \ldots, J$ and individuals $i = 1, \ldots, n$. Then, a large number of individuals having similar high probabilities of belonging to same clusters suggests that these clusters represent similar sets of preferences. Collecting $\phi = (\phi_1, \ldots, \phi_J)$, our current setup implies a mixture distribution of EASI regressions after marginalizing the cluster indicators:

$$p(\boldsymbol{w}_i^*, \boldsymbol{p}_i^* \mid \boldsymbol{\beta}, \boldsymbol{\gamma}, \boldsymbol{\Sigma}, \boldsymbol{\phi}) \propto \sum_{j=1}^J \phi_j \mathcal{N}_{s(M_p+3)}(\boldsymbol{w}_i^*, \boldsymbol{p}_i^* \mid \boldsymbol{\mu}_{ij}, \boldsymbol{\Sigma}_j).$$

For simplicity in the notation for what follows, we assume that for each individual the share variables are ordered such that the first set is all the goods with no consumption and the remaining are for the goods with positive consumption. That is, for each individual *i* there are $N_i = s - |L_i|$ shares with $w_{il} = 0$ for $l = 1, \ldots, N_i$ and the remaining are positive; $w_{il} > 0$ for $l = N_i + 1, \ldots, s$. We can then partition

$$\boldsymbol{F}_{i}\boldsymbol{\beta} = \begin{bmatrix} \boldsymbol{F}_{i}^{-}\boldsymbol{\beta}_{j}^{-} \\ \boldsymbol{F}_{i}^{+}\boldsymbol{\beta}_{j}^{+} \end{bmatrix} \quad \text{and} \quad \boldsymbol{\Sigma}_{j} = \begin{bmatrix} \boldsymbol{\Sigma}_{j,\boldsymbol{\varepsilon}_{i}^{-}\boldsymbol{\varepsilon}_{i}^{-}} & \boldsymbol{\Sigma}_{j,\boldsymbol{\varepsilon}_{i}^{-}\boldsymbol{\tau}_{i}} \\ \boldsymbol{\Sigma}_{j,\boldsymbol{\tau}_{i}\boldsymbol{\varepsilon}_{i}^{-}} & \boldsymbol{\Sigma}_{j,\boldsymbol{\tau}_{i}\boldsymbol{\tau}_{i}} \end{bmatrix},$$
(10)

where $\boldsymbol{\varepsilon}_i^- = [\varepsilon_{i1}, \ldots, \varepsilon_{iN_i}], \, \boldsymbol{\varepsilon}_i^+ = [\varepsilon_{i(N_i+1)}, \ldots, \varepsilon_{is}], \, \boldsymbol{\tau}_i = [\boldsymbol{\varepsilon}_i^{+\top}, \boldsymbol{u}_i^{\top}]^{\top}$, and $\boldsymbol{F}_i^-, \, \boldsymbol{F}_i^+, \, \boldsymbol{\beta}_j^-$, and $\boldsymbol{\beta}_j^+$ are appropriate partitions of the variables and coefficients, respectively.

3.3 Bayesian Estimation

We implement a Bayesian inferential framework that allows us to simultaneously handle all key elements of this framework: heterogeneity in structural preferences, censoring at corner solutions, endogeneity, and imposition of microeconomic restrictions. The point of departure is a prior probabilistic belief about unknown parameters, collected into $\boldsymbol{\theta}$, which is updated using sample information \mathcal{D} . Letting $p(\mathcal{D} \mid \boldsymbol{\theta})$ represent the likelihood function and $\pi(\boldsymbol{\theta})$ be the prior distribution, we can use Bayes' rule to obtain the posterior distribution as

$$\pi(\boldsymbol{\theta}|\mathcal{D}) \propto p(\mathcal{D} \mid \boldsymbol{\theta}) \times \pi(\boldsymbol{\theta}).$$

Having specific the likelihood function characterizing our econometric model, we are simply left with providing a prior specification for estimation. Motivated by the structure of our problem, we assume the following conditionally conjugate priors for their computational convenience, with an added twist:

$$\beta_{j} \stackrel{iid}{\sim} \mathcal{N}_{d_{\beta}}(\underline{\beta}_{j}, \underline{B}_{j}), \quad j = 1, \dots, J$$

$$\gamma \sim \mathcal{N}_{d_{\gamma}}(\underline{\gamma}, \underline{\Gamma})$$

$$\psi_{i} \mid \phi \stackrel{iid}{\sim} \text{Categorical}(\phi), \quad i = 1, \dots, n$$

$$\phi \sim \text{Dirichlet}(\underline{\alpha})$$

$$I$$

$$(11)$$

$$\pi(\mathbf{\Sigma}) = \mathcal{IW}(\mathbf{\Sigma}_{uu} \mid \underline{\nu}_{uu} - s, \underline{\mathbf{R}}_{uu}) \times \prod_{j=1}^{\circ} \mathcal{IW}(\mathbf{\Sigma}_{j,\varepsilon\varepsilon\cdot u} \mid \underline{\nu}_{j}, \underline{\mathbf{R}}_{j,\varepsilon\varepsilon\cdot u}) \mathcal{MN}(\mathbf{\Sigma}_{j,u\cdot u\varepsilon} \mid \underline{\mathbf{R}}_{j,u\cdot u\varepsilon}, \underline{\mathbf{R}}_{uu}^{-1}, \mathbf{\Sigma}_{j,\varepsilon\varepsilon\cdot u}),$$

where \mathcal{IW} is the inverse-Wishart distribution and \mathcal{MN} is the matrix-normal distribution. The factored prior on Σ takes into account the model structure by connecting the homogeneous first-stage equation with the cluster-specific structural equations.⁸

Collect the endogenous observables $\boldsymbol{w} = [\boldsymbol{w}_1^{\top}, \dots, \boldsymbol{w}_n^{\top}]^{\top}$ and $\boldsymbol{p}^* = (\boldsymbol{p}_1^{\top^*}, \dots, \boldsymbol{p}_n^{\top^*})^{\top}$, observable exogenous variables $\boldsymbol{G} = [\boldsymbol{G}_1^{\top}, \dots, \boldsymbol{G}_n^{\top}]^{\top}$, latent variables $\boldsymbol{w}^* = [\boldsymbol{w}_1^{*\top}, \dots, \boldsymbol{w}_n^{*\top}]^{\top}$, and cluster indicators $\boldsymbol{\psi} = (\psi_1, \dots, \psi_n)$. Similarly, collect all parameters $\boldsymbol{\beta}, \boldsymbol{\gamma}, \boldsymbol{\Sigma}, \boldsymbol{\psi}, \boldsymbol{\phi}$ (augmented with \boldsymbol{w}^*) into $\boldsymbol{\theta}$, and collect the observable shares and exogenous characteristics into $\mathcal{D} = (\boldsymbol{w}, \boldsymbol{p}^*, \boldsymbol{G})$. Combining the likelihood with the joint prior using Bayes' rule, the joint posterior for the augmented parameters can be expressed as

$$p(\boldsymbol{\theta} \mid \mathcal{D}) \propto \prod_{i=1}^{n} \prod_{l=1}^{s} \left[\mathbb{1}(w_{il} = 0) \mathbb{1}(w_{il}^{*} \leq 0) + \mathbb{1} \left(w_{il} = \frac{w_{il}^{*}}{\sum_{j \in L_{i}} w_{ij}^{*}} \right) \mathbb{1}(w_{il}^{*} > 0) \right] \\ \times \prod_{j=1}^{J} \mid \boldsymbol{\Sigma}_{j} \mid^{-\frac{n_{j}}{2}} \exp \left\{ -\frac{1}{2} \sum_{i \in C_{j}} \left[\begin{matrix} \boldsymbol{w}_{i}^{*} - \boldsymbol{F}_{i}\boldsymbol{\beta}_{j} \\ \boldsymbol{p}_{i}^{*} - \boldsymbol{G}_{i}\boldsymbol{\gamma} \end{matrix} \right]^{\top} \left[\begin{matrix} \boldsymbol{\Sigma}_{j,\varepsilon\varepsilon} & \boldsymbol{\Sigma}_{j,\varepsilon u} \\ \boldsymbol{\Sigma}_{j,u\varepsilon} & \boldsymbol{\Sigma}_{uu} \end{matrix} \right]^{-1} \left[\begin{matrix} \boldsymbol{w}_{i}^{*} - \boldsymbol{F}_{i}\boldsymbol{\beta}_{j} \\ \boldsymbol{p}_{i}^{*} - \boldsymbol{G}_{i}\boldsymbol{\gamma} \end{matrix} \right] \right\}$$
(12)
$$\times \prod_{j=1}^{J} \pi(\boldsymbol{\beta}_{j}) \times \pi(\boldsymbol{\gamma})\pi(\boldsymbol{\Sigma}) \times \prod_{i=1}^{n} \pi(\psi_{i} \mid \boldsymbol{\phi})\pi(\boldsymbol{\phi}) ,$$

where, for j = 1, ..., J, $C_j = \{i : \psi_i = j\}$ is the *j*-th cluster of observations and $n_j = |C_j| = \sum_{i=1}^n \mathbb{1}(\psi_i = j)$ is the number of individuals in the cluster. Using this expression, standard updates lead us to the following conditional posteriors for the model parameters (where the notation $\boldsymbol{\theta}_{-\theta_1}$ represents the vector of parameters $\boldsymbol{\theta}$ with component $\boldsymbol{\theta}_1$ removed):

$$\beta_{j} \mid \boldsymbol{\theta}_{-\beta_{j}}, \mathcal{D} \stackrel{iid}{\sim} \mathcal{N}_{d_{\beta}}(\bar{\beta}_{j}, \bar{B}_{j}), \quad j = 1, \dots, J$$

$$\gamma \mid \boldsymbol{\theta}_{-\gamma}, \mathcal{D} \sim \mathcal{N}_{d_{\gamma}}(\bar{\gamma}, \bar{\Gamma}),$$

$$\psi_{i} \mid \boldsymbol{\theta}_{-\psi_{i}}, \mathcal{D} \stackrel{iid}{\sim} \text{Categorical}(\bar{\phi}_{i}), \quad i = 1, \dots, n$$

$$\phi \mid \boldsymbol{\theta}_{-\phi}, \mathcal{D} \sim \text{Dirichlet}(\bar{\alpha}),$$

$$\pi(\boldsymbol{\Sigma} \mid \boldsymbol{\theta}_{-\Sigma}, \mathcal{D}) = \mathcal{IW}(\boldsymbol{\Sigma}_{uu} \mid \bar{\nu}_{uu}, \bar{R}_{uu}) \times \prod_{j=1}^{J} \mathcal{IW}(\boldsymbol{\Sigma}_{j,\varepsilon\varepsilon \cdot u} \mid \bar{\nu}_{j}, \bar{R}_{j}) \mathcal{MN}(\boldsymbol{\Sigma}_{j,u \cdot u\varepsilon} \mid \bar{M}_{j}, \bar{U}_{j}, \boldsymbol{\Sigma}_{j,\varepsilon\varepsilon \cdot u}),$$
(13)

⁸We also provide implementation and results with heterogeneous first-stage regressions below as a comparison.

with posterior hyperparameters

$$\begin{split} \bar{B}_{j} &:= \left(\underline{B}_{j}^{-1} + \sum_{i \in C_{j}} F_{i}^{\top} \Sigma_{j, \varepsilon \cdot u}^{-1} F_{i}\right)^{-1}, \quad j = 1, \dots, J \\ \bar{B}_{j} &:= \bar{B}_{j} \left\{ \underline{B}_{j}^{-1} \underline{\beta}_{j} + \sum_{i \in C_{j}} F_{i}^{\top} \Sigma_{j, \varepsilon \cdot u}^{-1} \left[w_{i}^{*} - \Sigma_{j, w \cdot u \varepsilon}^{\top} (p_{i}^{*} - G_{i} \gamma) \right] \right\}, \quad j = 1, \dots, J , \end{split}$$

$$\begin{split} \Sigma_{j, \varepsilon \cdot u} &:= \Sigma_{j, \varepsilon \varepsilon} - \Sigma_{j, \varepsilon u} \Sigma_{u 1 u}^{-1} \Sigma_{j, u v \cdot \varepsilon}^{\top} G_{i}^{\top} \sum_{j, u v \cdot \varepsilon}^{-1} J_{i} = 1, \dots, J , \\ \bar{\Gamma} &:= \left[\underline{\Gamma}^{-1} + \sum_{j=1}^{J} \sum_{i \in C_{j}} G_{i}^{\top} \Sigma_{j, u v \cdot \varepsilon}^{-1} \left[p_{i}^{*} - \Sigma_{j, \varepsilon \cdot v}^{\top} (w_{i}^{*} - F_{i} \beta_{j}) \right] \right\}, \end{split}$$

$$\begin{split} \Sigma_{j, \varepsilon \cdot u} &:= \Sigma_{u u} - \Sigma_{j, \varepsilon u}^{\top} \sum_{j \neq \varepsilon}^{J} \sum_{j \in C_{j}} G_{i}^{\top} \Sigma_{j, u v \cdot \varepsilon}^{-1} \left[p_{i}^{*} - \Sigma_{j, \varepsilon \cdot v}^{\top} (w_{i}^{*} - F_{i} \beta_{j}) \right] \right\},$$

$$\end{split}$$

$$\begin{split} \Sigma_{j, \varepsilon \cdot u} &:= \Sigma_{u u} - \Sigma_{j, \varepsilon u}^{\top} \sum_{j \neq \varepsilon}^{J} \sum_{j \in C_{j}} G_{i}^{\top} \Sigma_{j, u v \cdot \varepsilon}^{-1} \left[p_{i}^{*} - F_{i} \beta_{j} \right] \right], \qquad i = 1, \dots, J,$$

$$\bar{\phi}_{i j} &:= \frac{\phi_{j} N_{i j}}{\sum_{j = 1}^{J} \phi_{j} N_{i j}}, \qquad i = 1, \dots, J, \qquad (16)$$

$$\bar{a}_{j} &:= \alpha_{j} + n_{j}, \qquad j = 1, \dots, J. \\ \bar{b}_{u u} &:= \nu_{u u} - s + n, \\ R_{u u} &:= R_{u u} + \sum_{i = 1}^{n} (p_{i}^{*} - G_{i} \gamma) \sum_{i \in C_{j}}^{\top} (w_{i}^{*} - F_{i} \beta_{j}) (w_{i}^{*} - F_{i} \beta_{j})^{\top}, \qquad j = 1, \dots, J, \\ \bar{b}_{i u} &:= \nu_{j} + n_{j}, \qquad j = 1, \dots, J, \\ \bar{b}_{i u} &:= \mu_{u u} - s + n, \\ R_{u u} &:= R_{u u} + \sum_{i = 1}^{n} (p_{i}^{*} - G_{i} \gamma) (p_{i}^{*} - G_{i} \gamma)^{\top}, \qquad j = 1, \dots, J, \\ \bar{b}_{j} &:= R_{j, \varepsilon \cdot u} - M_{j}^{\top} \overline{U}_{j}^{-1} M_{j} + \sum_{i \in C_{j}} (w_{i}^{*} - F_{i} \beta_{j}) (w_{i}^{*} - F_{i} \beta_{j})^{\top}, \qquad j = 1, \dots, J, \\ \bar{U}_{j} &:= \left[R_{u u} + \sum_{i \in C_{j}} (p_{i}^{*} - G_{i} \gamma) (p_{i}^{*} - G_{i} \gamma)^{\top} \right]^{-1}, \qquad j = 1, \dots, J, \\ \bar{M}_{j} &:= \bar{U}_{j} \left[R_{j, w v \varepsilon} + \sum_{i \in C_{j}} (p_{i}^{*} - G_{i} \gamma) (w_{i}^{*} - F_{i} \beta_{j})^{\top} \right]^{-1}, \qquad j = 1, \dots, J, \\ \bar{M}_{j} &:= \bar{U}_{j} \left[R_{j, w v \varepsilon} + \sum_{i \in C_{j}} (p_{i}^{*} - G_{i} \gamma) (w_{i}^{*} - F_{i} \beta_{j})^{\top} \right]^{-1}, \qquad j = 1, \dots, J, \end{aligned}$$

For each individual i, we now provide the posterior of the latent shares \boldsymbol{w}_i^* conditional on model parameters and data. Using the partitions given in (10), and assuming the individual belongs to an arbitrary cluster such that $i \in C_j$, the relevant conditional posterior is

$$\boldsymbol{w}_{i}^{*-} \mid \boldsymbol{\theta}_{-\boldsymbol{w}_{i}^{*-}}, \mathcal{D} \sim \\ \operatorname{TM}\mathcal{N}_{(-\infty,0]^{N_{i}}} \left(\boldsymbol{F}_{i}^{-}\boldsymbol{\beta}_{j}^{-} + \boldsymbol{\Sigma}_{j,\boldsymbol{\varepsilon}_{i}^{-}\boldsymbol{\tau}_{i}} \boldsymbol{\Sigma}_{j,\boldsymbol{\tau}_{i}\boldsymbol{\tau}_{i}}^{-1} \begin{bmatrix} \boldsymbol{w}_{i}^{+} - \boldsymbol{F}_{i}^{+}\boldsymbol{\beta}_{j}^{+} \\ \boldsymbol{p}_{i}^{*} - \boldsymbol{G}_{i}\boldsymbol{\gamma} \end{bmatrix}, \boldsymbol{\Sigma}_{j,\boldsymbol{\varepsilon}_{i}^{-}\boldsymbol{\varepsilon}_{i}^{-}} - \boldsymbol{\Sigma}_{j,\boldsymbol{\varepsilon}_{i}^{-}\boldsymbol{\tau}_{i}} \boldsymbol{\Sigma}_{j,\boldsymbol{\tau}_{i}\boldsymbol{\tau}_{i}}^{-1} \boldsymbol{\Sigma}_{j,\boldsymbol{\tau}_{i}\boldsymbol{\varepsilon}_{i}^{-}} \right), \quad (18)$$

where $\text{TM}\mathcal{N}_{\mathcal{S}}$ represents a multivariate normal distribution truncated to region \mathcal{S} . In our case, $\mathcal{S} = \times_{j=1}^{N_i} (-\infty, 0]$ so that the truncation region is simply the Cartesian product of N_i negative half-open in-

tervals to 0. For computational stability, we center the posterior at the observed positive shares (\boldsymbol{w}_i^+) rather than the latent ones (\boldsymbol{w}_i^{*+}) . Finally, conditional on the drawn negative latent shares, the positive share components have a degenerate density that places all mass at $w_{il}^{*+} = (1 - \sum_{j=1}^{N_i} w_{ij}^{*-})w_{i(N_i+l)}$ for each $l = 1, \ldots, |L_i|$.

Based on these expressions, we provide a Gibbs sampler that can obtain draws from the joint posteriors. First, conditional on a given value of the latent shares, we obtain a new draw of the model parameters using (13). We then draw the latent shares with zero consumption from conditional on those with positive consumption using (18) and re-compute all latent shares. Repeating this process S times leaves us with a chain of posterior draws ($\theta^{(1)}, \ldots, \theta^{(S)}$) that we can use to summarize model estimates. Additional details on the computational implementation of our algorithm can be found in Appendix A.

4 Results

We now explore the results of applying our previously described methodology to the analysis of demand for illicit drugs in Colombia. We use the full sample of 1,236 consumers contained in the nationally representative 2019 *ENCSPA* survey to provide Bayesian inference of the EASI demand system specified by equations (6), (8) and (11). In the specification, we include as exogenous information all the variables whose descriptive statistics are presented in Table 2 except for the geographically distance-weighted variables. To save on degrees of freedom and as recommended by Lewbel and Pendakur (2009), we include these demographics directly in the equation and only explore interactions between price and indirect utility, rather than including additional observed heterogeneity that can greatly increase the size of the estimated demand system.

Our estimation framework also takes endogeneity issues into account. A first source of endogeneity arises mechanically from (2), with budget shares used to construct indirect utility, creating simultaneous causality. However, it has been documented in the literature that this endogeneity is numerically negligible (Lewbel and Pendakur, 2009, Zhen et al., 2014). A second —and likely more relevant in a micro setting— source of endogeneity comes through the prices, due to possible reverse causality, omitted variables and measurement errors. Reverse causality is not of concern when working with micro-level data sets, as one can argue individual purchase decisions should not affect aggregate market prices. However, the latter two sources are relevant when working with micro-level data sets, as these are not averaged out when aggregated. For instance, omitted variables can arise through the strategic search of consumers when looking for drug providers, particularly in markets where individuals declare to have easy access to drugs, which translates to relatively good price information and potentially many providers (see Galenianos and Gavazza, 2017, for a structural market model for illicit drugs). Additionally, the prices provided in our data are self-reported by individuals, meaning they can be subject to non-classical measurement errors created by recall, socially desirable responses, or other self-reporting biases (Embree and Whitehead, 1993, Johnson and Fendrich, 2005, Fadnes et al., 2009, Steenkamp et al., 2010, Rosenman et al., 2011).

We tackle potential issues of endogeneity in our application by using instrumental variables based on two sources of information. First, the number of drug-related captures in the neighborhood of the individual allows us to consider supply-side effects exploiting random variation in availability of drug dealers. Second, we use a secondary source of prices to deal with potential search effects (interactions between consumers and dealers) and misreporting by individuals, where these instruments are prices imputed as geographicallyweighted averages of the prices in drug dens. As the prices in these locations is both standardized and less prone to measurement error, we can control for additional demand-side variation in consumer prices (a similar strategy is used in Zhen et al., 2014). We use bivariate Gaussian kernels with bandwiths of 1,000 kms centered at the latitude/longitude coordinates of each consumer in our sample to construct distance-weighted instruments based on the geo-referenced locations of surveyed individuals.

In our implementation, we set the prior hyperparameters to standard non-informative values: for $j = 1, \ldots, J$, $\underline{\beta}_j = \mathbf{0}_{d_\beta}, \underline{B}_j = 1000 \mathbf{I}_{d_\beta}, \underline{\gamma} = \mathbf{0}_{d_\gamma}, \underline{\Gamma} = 1000 \mathbf{I}_{d_\gamma}, \underline{\alpha} = (1/J) \mathbf{1}_J, \underline{\nu}_j = s(M_p + 3), \underline{\nu}_{uu} = s(M_p + 3)$, and $\underline{\mathbf{R}} = \mathbf{I}_{s(M_p+3)}$. We initially set three clusters in our application (J = 3). However, we found that one cluster disappeared after discarding the burn-in iterations. Thus, we fixed the number of components at J = 2, as supported by the variability in the data and instruments. We do not implement any random permutation of the cluster identifiers (Frühwirth-Schnatter, 2006), as this was shown to hinder convergence of our Gibbs sampler in simulation exercises. We also verify label-switching is not an issue in our application by considering the consistency of individual segmentation of posterior chains (results available upon request).

Using our coefficient draws $(\boldsymbol{\theta}^{(1)}, \ldots, \boldsymbol{\theta}^{(S)})$ from the EASI specification (allowing or not for unobserved heterogeneity clusters), we can use the posterior draws to compute all relevant microeconomic summaries previously derived in Table 3. We are then left with posterior draws of these summaries, such that inference on these highly non-linear quantities is a simple by-product of the estimation algorithm; a key feature of Bayesian inference. The coefficients of the EASI model itself are usually not of direct interest, so we provide the full estimates in the Appendix tables B.1, B.2 and B.3. Nonetheless, we highlight that these estimates provide evidence for: (i) the importance of including demographic variables to deal with observed heterogeneity in consumer preferences; (ii) the chosen instruments being relevant and jointly significant in explaining additional variation in drug prices aside from the demographics; and (iii) prices being endogenous due to the significant correlation to consumed shares in their latent disturbances.

We then turn to studying the unobserved heterogeneity clusters recovered by our method, and provide evidence that these identify two clear consumer segments: recreational (or "safe") consumers and hard users (termed here as "addicts"). We show how the classification into these population segments is correlated to addiction indicators that can be obtained from the survey and that one of the identified segments has similar drug consumption patterns to the population of homeless individuals whom showcase large levels of drug consumption, providing further rationale behind our cluster labels. Additionally, we provide balance tests across variables of interest to further understand the main differences between these population segments. Our results confirm that access to and use of harder drugs (among other key demographic variables) are drivers of the classification into one cluster or another. Importantly, these groups are recognized by the algorithm without the need to model the factors behind heterogeneity in preferences and without introducing any prior information on the cluster assignment.

An important aspect of our Bayesian inferential framework is that it allows us to test the microeconomic restrictions imposed for estimation of the EASI demand system. As discussed in Section 3.1, while the unit-sum restrictions are imposed due to a mechanical property of expenditure shares, the constraints from Slutsky symmetry, strict cost monotonicity and cost concavity are not innocuous as a way to regularize demand behaviour towards microeconomic theory predictions. As Slutsky symmetry implies an equality (or point) restriction, we can use the Savage-Dickey density ratio to calculate the Bayes factor in favor of the restriction.⁹ For cost monotonicity and concavity, which imply inequality (or set) restrictions, we can directly calculate the Bayes factor according to the posterior probability that the constraints are satisfied in

⁹Let M_1 represent the EASI model imposing Slutsky symmetry and M_2 the unrestricted model. Recall that Slutsky symmetry imposes $\widetilde{A}_m = \widetilde{A}_m^{\top}$ for $m = 0, ..., M_p$ and $\widetilde{B} = \widetilde{B}^{\top}$, meaning M_1 imposes an equality restriction on the model parameters of the form $\theta = \theta_0$. The Bayes factor comparing models M_1 and M_2 can then be computed

our MCMC draws. Computing these measures for our specification of interest results in very strong evidence in favor of Slutsky symmetry ($2 \log BF_{1,2} = 17.58$), strong evidence in favor of strict cost monotonicity ($2 \log BF_{1,2} = 8.56$), and only slight evidence in favor of cost concavity ($2 \log BF_{1,2} = 1.84$). Evidence generally points towards microeconomic restrictions being satisfied in-sample using the Bayes factor scale provided in Kass and Raftery (1995).

4.1 Demand-Price Elasticities

Our first set of results considers the price effects on demand of illicit drugs. As we model the demand of drugs in a fully structural system, we can obtain not just the own-price elasticities of each drug (as usually done in the literature), but also the cross-price elasticities of one drug onto another. This is of particular importance in the face of potential marijuana legalization policies that are likely to have large impacts through price, as the price of one drug will face clear changes due to policy intervention whereas the price paths of other drugs will likely remain fixed in the short-term. In this way, we will be able to study how the effect of a price change due to legalization translates into re-balancing of a consumer's drug bundle.

The main story behind the results is presented in Table 4, which provides estimates from all our Bayesian specifications. The panels of the table are arranged in the way we were lead by our exploration of the different specifications and understanding of the data. We begin by considering estimation of the EASI model accounting for corner solutions (censoring) due to zero consumption of drugs by many consumers, before augmenting the model with price endogeneity and using external instruments to recover identification (two top panels in Table 4). Both models do not account for unobserved heterogeneity. In the endogenous specification, the relevance of endogeneity is evident when comparing the two sets of results, as the inclusion of instruments highlights the high levels of price sensitivity in cocaine and basuco. However, this comes at the cost of a remarkably reduced precision. These results align with previous literature that has found marijuana to be an inelastic product in countries such as Australia (Jacobi and Sovinsky, 2016), Colombia (Ramírez-Hassan et al., 2023), South Africa (Riley et al., 2020), Thailand (Sukharomana and Chang, 2017), and the United States (Davis et al., 2016). On the other hand, the demand for more harmful drugs, like cocaine and basuco, has shown greater elasticity (Jofre-Bonet and Petry, 2008, Gallet, 2014). Regarding cross-price elasticities, limited evidence finds some complementarity between marijuana and cocaine (Jofre-Bonet and Petry, 2008).¹⁰

Our next two specifications introduce unobserved heterogeneity by considering two clusters. The results presented are for the identified "safe" or recreational cluster, whose parameter estimates are the most stable (those for the "addict" cluster are highly unstable or not updated through the data due to the small sample size of this cluster). Again, we observe the relevance of endogeneity when comparing these two sets of posterior estimates. We improve the precision of the posterior estimates by fixing the parameters of the first stage to be homogeneous across clusters and, consequently, fully exploiting the variability in the instruments, leaving only unobserved heterogeneity in the structural demand equation.¹¹

using only the unrestricted model according to the Savage-Dickey density ratio (see Kass and Raftery, 1995):

$$BF_{1,2} = p(\boldsymbol{\theta} = \boldsymbol{\theta}_0 \mid \mathcal{D}, M_2) / p(\boldsymbol{\theta} = \boldsymbol{\theta}_0 \mid M_2).$$

¹⁰Tables B.4 (full sample) and B.5 ("safe" cluster) in the Appendix show similar patterns using least squares (LS) and two-stage LS. However, these estimators do not account for censoring nor unobserved heterogeneity.

¹¹The two bottom panels in Table B.5 in the Appendix show the results assuming heterogeneity in the price equations. We observe greater variability in the results.

We focus the remaining analysis of the results based on the last specification with a homogeneous firststage. This specification identifies a total of 1,069 "safe" consumers in our sample, representative of 551,507 drug consumers nationwide (the remaining 167 in-sample consumers classified as "addicts" represent 81,983 national consumers). The demand-price elasticity estimates from this specification suggest that recreational consumers are unit-elastic to the price of illicit drugs (a 1% increase in price implies a 1% decrease in consumption), such that they are highly responsive and their consumption follows the rational law of demand. These elasticities are statistically significant, as the 95% credible intervals do not include zero. The similarity of these own-price elasticities is novel compared to previous literature, which clearly identifies greater price sensitivity for harmful drugs than for marijuana. See the panel *Bayesian Censored with Endogeneity but without Mixtures* in Table 4. The difference arises as previous literature does not account for unobserved heterogeneity, identifying quantities that mix together individuals with different unobserved preferences. In particular, we show below that the "safe" cluster spends the most on marijuana, with a small percentage spent on cocaine and basuco. As a result, price variations in these two drugs do not have a high impact on their spending, and consequently, the price elasticity exhibits similar values to those found for marijuana. Unobserved preference heterogeneity is therefore crucial for identifying meaningful price effects.

Additionally, as we have the cross-price elasticities of demand, we can determine that both harder drugs cocaine and basuco are complementary to marijuana in the sense that it follows the same direction to the own-price effect of marijuana (a 1% increase in the price of marijuana results in a decrease of 0.03% in the quantity of cocaine and 0.11% for basuco). Similarly, marijuana responds in the same direction to changes in the price of harder drugs, suggesting further complementarity, though the magnitude of this effect is one or two orders of magnitude smaller such that the complementarity is asymmetric. Finally, we note that cocaine and basuco are instead substitutes, as can be expected from basuco being a lower-quality product and being considered and inferior good to cocaine. Our estimates suggest a 1% increase in the price of basuco results in an increase in the consumption of only 0.03%. This is in line with the much larger average price per gram of cocaine, such that a 1% increase in the price of cocaine has larger level effects on expenditure than the corresponding increase for basuco. However, the uncertainty associated to the cross-price elasticities varies and the 95% credible intervals include zero, with a high probability of a complementary effect between marijuana and cocaine remaining as the key effect, which is consistent with previous literature.

The full marginal posterior distributions of these summaries can be visualized in Figure 7. The intervals presented in the table are the 95% highest posterior density intervals of these densities. We present additional visualizations of these posteriors in the Appendix figures B.1 and B.2. The draws are shown to satisfy standard posterior convergence diagnostics such that posterior expectations should be accurately computed (results available upon request).

4.2 Consumer Segments by Drug Preferences

The finite mixture framework used in this paper allows us to provide posterior estimates of both cluster indicators and probability of belonging to each cluster, each over all individuals in our sample. We first provide evidence that the clusters identified by our algorithm are stable, in the sense that the classification of individuals is sharp and consistent across posterior draws. Figure 8 showcases the posterior inclusion probability to C_1 , normalized to be the "safe" cluster of consumers, denoted as $\phi_{i,1}$ in (16). Observe that there is a sharp edge that distinguishes the probability of inclusion of individuals to the "safe" and "addict" clusters, with a few individuals falling on the frontier between these two states. This provides a way for

Good demand	Price Marijuana	Price Cocaine	Price Basuco
	Bayesian Censo	ored without Mixtures	
Marijuana	-0.9747 (-0.9986, -0.9522)	$\begin{array}{c} -0.0118 \\ (-0.0291, 0.0065) \end{array}$	-0.0096 (-0.0203, 0.0007)
Cocaine	-0.1401 (-0.3017, 0.0196)	$\begin{array}{c} -0.9715 \\ (-1.1213, -0.8265) \end{array}$	$0.0637 \\ (-0.0115, 0.1415)$
Basuco	$-0.2857 \\ (-0.7106, 0.1122)$	$\begin{array}{c} 0.2980 \\ (-0.0447, 0.6471) \end{array}$	-0.9379 (-1.3188, -0.5238)
Baye	esian Censored with E	ndogeneity but withou	at Mixtures
Marijuana	-0.9734 (-1.0109, -0.9365)	-0.0182 (-0.0641, 0.3063)	$\begin{array}{c} -0.0042 \\ (-0.2155, 0.0235) \end{array}$
Cocaine	-0.2315 (-0.5874, 0.7247)	-1.2466 (-7.1771, -0.6637)	$\begin{array}{c} 0.4256 \\ (-0.0241, 3.8440) \end{array}$
Basuco	$0.0747 \\ (-3.2705, 1.0507)$	$\begin{array}{c} 1.9327 \\ (-0.0268, 18.0337) \end{array}$	$\begin{array}{c} -2.8755\\ (-11.1489, -0.6727)\end{array}$
Ba	ayesian Censored inclu	ding Mixtures ("Safe"	cluster)
Marijuana	-1.0114 (-1.0566, -0.9718)	-0.0524 (-0.0864, -0.0075)	$\begin{array}{c} -0.0323\\ (-0.0645, -0.0032)\end{array}$
Cocaine	-0.2613 (-0.6248, 0.1276)	$\begin{array}{c} -0.7202 \\ (-1.1246, -0.3807) \end{array}$	$0.0766 \\ (-0.1409, 0.2683)$
Basuco	$2.0414 \\ (-0.5318, 3.5122)$	$0.6582 \ (-0.2391, 1.3353)$	$\begin{array}{c} -0.1528 \\ (-1.4840, 1.4202) \end{array}$
	Bayesian Censo including Mixt	ored with Endogeneity cures ("Safe" cluster)	
Marijuana	-0.9863 (-1.0151, -0.9580)	-0.0115 (-0.0402, 0.0153)	$\begin{array}{c} 0.0019 \\ (-0.0137, 0.0182) \end{array}$
Cocaine	$-0.1362 \\ (-0.3599, 0.0849)$	$\begin{array}{c} -0.8395 \\ (-1.1893, -0.4436) \end{array}$	$-0.0668 \\ (-0.3952, 0.2458)$
Basuco	$\begin{array}{c} 0.1126 \\ (-0.4680, 0.6756) \end{array}$	-0.2893 (-1.7641, 1.1189)	$-0.7685 \ (-2.2193, 0.8167)$
1	Bayesian Censored wit Homogeneous Price	h Endogeneity and M Equations ("Safe" clu	ixtures, ster)
Marijuana	-0.9926 (-1.0068, -0.9789)	-0.0035 (-0.0168, 0.0101)	-0.0009 (-0.0101, 0.0082)
Cocaine	-0.0309 (-0.1445, 0.0845)	-1.0036 (-1.1808, -0.8148)	$\begin{array}{c} 0.0335\\ (-0.1156, 0.1875)\end{array}$
Basuco	-0.1197 (-0.6103, 0.2965)	$\begin{array}{c} 0.1350 \\ (-0.5200, 0.8276) \end{array}$	-1.1167 (-1.8297, -0.3921)

 Table 4: Price elasticities of demand obtained from Bayesian estimates across several specifications and varied samples of consumers

Notes: Identified Safe includes 1,069 consumers. Final panel uses full sample of 1,236 consumers for the first-stage regression. 95% highest posterior density (HPD) intervals are provided.



Figure 7: Density plots of price elasticities of demand implied by EASI system estimates

Notes: Full posterior density over price elasticity of demand parameters (own and crossed between illicit drugs). Dashed line represents median of chains, dotted line provides the 95% HPD for each parameter, and a solid line at 0 is drawn for reference. Single chain run of 10000 after a burn-in window of 5000 iterations.



Figure 8: Inclusion probability to identified Safe cluster

Notes: Sorted by the individual-specific posterior probability of inclusion to the Safe cluster.

the model to identify individuals that can be assigned to either cluster, which can be interpreted in our application as being at risk of moving between being a recreational consumer towards addiction.

Based on this classification, we can probe the differences between the characteristics of individuals that are sorted into either cluster. Figure 9 presents the consumption shares of individuals classified into the "safe" or "addict" clusters. One of the main reason behind this labeling is the fact that consumers classified into the second cluster have larger shares of both cocaine and basuco compared to the share of marijuana. Given the more addictive nature of these substances, when individuals include them in their consumption bundle, it is more likely that this will be correlated to negative outcomes in terms of their covariates. In this figure we additionally highlight a subset of the population that can be thought of as "at-risk" due to their potential of moving from the first to second cluster.

To add further evidence to the rationale behind our cluster labels, we evaluate the average differences between all relevant covariates we collect in the survey. Figure 10 showcases the sorted T-statistics obtained from a mean-difference test that takes into account the different cluster sizes (see numerical p-values and intervals in Table B.6 in the Appendix). The largest differences between the "addict" and "safe" clusters arise due to the former having higher access to and consumption of both cocaine and basuco, including addiction-related questions contained in the original survey. Other key differences in terms of demographic characteristics include larger probabilities that individuals are consumers of substances in their personal networks, have access to a drug dealer, and use tobacco and alcohol jointly for the "addict" cluster. Additionally, individuals in this cluster are older, report feeling mentally healthy less often, have less education, and are more likely to be male.



Figure 9: Shares of consumption of illicit drugs across clusters

Notes: Individuals in-sample classified according to the unobserved heterogeneity cluster assigned by our model. Additional "at-risk" group highlighted as "safe" consumers with controls more similar to the "addict" subpopulation, meaning they are at-risk of addiction. Random jitter is added to the consumption shares to highlight concentration of consumers at the edges and borders of the simplex. These individuals present zero consumption of at least one illicit drug.

Particular attention must be given to individuals belonging to the "addict" cluster, as their drug consumption patterns are similar to those of homeless individuals, who report basuco as the most consumed drug according to the Census of Homeless Individuals in Colombia (2019). We also examined the answers provided by the "addict" cluster to questions related to drug-related risks, such as issues with friends, family, or work due to drug consumption. We find that the addict group, on average, responded positively to 5 out of 8 questions, whereas this rate is measured to less than 1 in 8 for those in the "safe" cluster. Using this procedure, we identify a subset of the "safe" cluster classified as "at-risk" in our model (representing 5,716 individuals) who show indication of moving towards drug addiction (green triangles in Figure 9).

4.3 Engel Curves and Income Effects

While a majority of the changes due to legalization are likely to be presented through changes in drug prices, it is also important to consider how potential relaxations of consumers' budget restrictions influence their demand behaviour. In Section 2 we presented Engel curves for the full sample to support the use of the EASI model that could recover the flexible non-linear structure in these curves. We provide evidence that this non-linearity can also be recovered as a mixture of the behaviour of the two clusters.

Specifically, we first showcase in Figure 11 similar non-parametric estimates of Engel curves as before (see Figure 6), except that these are constructed for the identified "safe" cluster subsamples. The range of non-linearities in these curves are reduced across all drugs, such that quadratic polynomials are sufficient to capture the relevant curvature. The complexity of the Engel curves observed in Figure 6 arises from the combination of individuals with differences in unobserved preference heterogeneity. Once we uncover the

Figure 10: Balance test between clusters



Notes: T-statistic of a two-sided mean difference test between the identified "Addict" and "Safe" clusters. Plotted interval provides critical values for significance of the mean difference at 5% level.



Notes: Engel curves estimated using a local regression procedure (Cleveland et al., 2017). First derivative computed using simple sorted differences along a grid of expenditure values. Confidence intervals are point-wise 95% percentile-*t* intervals from 5,000 bootstrap replications. Engel curves for identified subsample exhibits patters closer to those expected from rational consumption.

hidden clusters, we observe less complex Engel curves.

We then show the Engel curves implied by our Bayesian estimates, along with their point-wise credibility intervals, in Figure 12. Note how the curves obtained from the "safe" cluster estimates closely align with the subsample's non-parametric estimates, particularly for marijuana and cocaine, the two explicitly modeled drugs. Observe that individuals with either larger or smaller expenditure around the median consume more marijuana, with a reverse situation occuring for cocaine and basuco, although the slope change occurs at approximately the median expenditure (slightly less than 0 centered expenditure for marijuana and cocaine, and slightly larger for basuco). Finally, note that the median behavior of the Engel curves for the "addict" cluster indicates that most of the expenditure is on basuco as drug expenditure increases; this highlights the addictive nature of the drug. However, the posterior estimates from this cluster are imprecise due to the small sample size in this group.

5 Marijuana legalization policy

In this section, we use our estimated drug demand behavior to conduct counterfactual exercises of the potential effects of a marijuana legalization policy. Following the large political backing that such a policy has already amassed in Colombia —as well as the legalization experience of Uruguay, a country both geographically and economically similar— it becomes crucial to understand its potential effects. This is emphasized by the idiosyncrasies of the Colombian drug market with its large production amounts, low costs, and salient demographics, as well as the large sources of heterogeneity in drug demand by consumers found in our estimation exercise.

Direct legalization policies will directly effect consumers' access to the drug and prices faced for its legal purchase. However, the final effect on marijuana price in Colombia is uncertain as legalization could entail conflicting effects in the market. Taking into account that the production cost of one gram of marijuana is US¢1 (Vélez-Torres et al., 2021), as well as factoring average logistical costs and the rate of return, the potential tax-free price of one gram (joint) should be US¢2, which matches the average tax-free price of a cigarette in Colombia (Ramírez-Hassan et al., 2023). However, the average market price of marijuana in Colombia is US¢83 (see Table 1), with most of this difference likely attributable to the illegality margin. On the other hand, marijuana legalization would introduce regulatory costs, such as taxes and bureaucracy, which could potentially dominate the final price (Caulkins et al., 2015).

We consider several scenarios based on the potential price changes of marijuana that such a legalization policy might entail (leaving all other drug prices fixed), considering a representative agent that did not have access to a dealer pre-implementation but now does have access due to legalization.¹² The first and most likely scenario is one of a 50% decrease in prices of marijuana, given the low production and distribution costs of marijuana in Colombia. This scenario mirrors Uruguay's recent experience following marijuana legalization, where the price of marijuana was reduced to incentivize demand in the newly legal market (Plúas-López, 2024). The second scenario considers the potential for legalization to decrease prices even further, setting the final price at 10% of the initial value. This would be comparable to the current taxincluded price of a cigarette in Colombia. Finally, a third scenario considers that the overhead costs of legalization might outweigh its cost benefits leading to a 25% net *increase* in the price of marijuana, similar

¹²We fix the values of the covariates for the representative agent to their means for continuously-distributed covariates (i.e., "average" agent) and to the mode for discretely-distributed covariates (i.e., "modal" agent). These values are fixed throughout the counterfactual exercises to make all results comparable.



Figure 12: Posterior Engel curves from EASI model for demand of illicit drugs across clusters

Notes: Left panel: individuals assigned into the "safe" cluster. Right panel: individuals assigned into the "addict" cluster. Engel curves computed as in Table 3 using Solid line plots Bayesian estimate of Engel curves (obtained as in Table) as the point-wise median over a grid of expenditure values. Point-wise Highest posterior density (HPD) intervals containing 90%, 95% and 99% posterior probability provided in blue. Left panel accurately reproduces results for the "safe" cluster (compare to the left panel of Figure 11). Engel curves from "addict" cluster do not exhibit rational economic behavior.

to the counterfactual exercise proposed by Jacobi and Sovinsky (2016).

We present results showcasing the counterfactual effects of this path of legalization policy on drug consumption, consumer welfare (as measured by the absolute value of Equivalent Variation), government revenue and illegal drug market size. As most demand system models are based on expenditure shares, they cannot identify changes to total expenditure nor changes in total quantities. Therefore, we approximate percentage changes to the consumed quantity of drug l (q_l) given a change to the price of drug j (p_j) as $\% \Delta q_l \approx \exp\{\tilde{\varepsilon}_{lj}^M \cdot \Delta \log(p_j)\} - 1$, where $\tilde{\varepsilon}_{lj}^M$ are the estimated demand-price elasticities (see Table 3). Given our Bayesian framework, we are able to provide full posterior distributions over these quantities, meaning inference also comes as a by-product of estimation. The uncertainty associated to our Bayesian results for the "safe" cluster implies highly accurate estimates of all quantities considered here.

We provide a full description of the results for the 50% decrease in the body of the paper, exploring alternative scenarios in Appendix B. Figure 13 shows the posterior distribution of the equivalent variation (EV) in annual terms following the price change, as deduced from the EASI model (Ramírez-Hassan and López-Vera, 2024):

$$EV = e\left[\exp\left\{-\sum_{l=1}^{S} \left(\tilde{w}_{l}^{1}\tilde{p}_{l}^{1} - \tilde{w}_{l}^{0}\tilde{p}_{l}^{0}\right) + \frac{1}{2}\sum_{l=1}^{S}\sum_{j=1}^{S}\tilde{a}_{lj}(\tilde{p}_{l}^{1}\tilde{p}_{j}^{1} - \tilde{p}_{l}^{0}\tilde{p}_{j}^{0})\right\} - 1\right] \times 12$$

where e is the total monetary expenditure in the three drugs, \tilde{w}_s^0 and \tilde{w}_s^1 are the pre and post legalization expenditure shares, \tilde{p}_s^0 and \tilde{p}_s^1 are pre and post (log) prices, and \tilde{a}_{sj} is the sj-th element of matrix \tilde{A}_0 , respectively. The result suggests that the representative "safe" consumer perceives a change in their utility that is equivalent to a median change in total expenditure of approximately \$363 USD, with a 95% credible interval of (338,374). This change is approximately equivalent to the annual average drug expenditure, meaning consumer welfare effects are considerable and largely due to an increased marijuana consumption that offsets the price decrease, with the remaining drugs experiencing negligible changes.

Figure 14 shows the predicted total expenditure on marijuana, cocaine, and basuco for current "safe" consumers under a 50% reduction in marijuana prices, classified by age group. To aggregate into a nationally representative quantity we use our survey expansion factors, approximating the new quantity and expenditures for each individual after modifying their reported price by 50% (as done for the representative agent). The shares and total expenditure closely resemble those in Figure 1. This is due to the unitary own-price elasticity of marijuana, unchanged prices for cocaine and basuco, and the relatively low shares of expenditure on these latter drugs.

After the legalization is implemented, previous studies suggest only a fraction of users will switch to the legal marijuana market, leaving approximately 34% of the illegal market active (Ramírez-Hassan et al., 2023, Plúas-López, 2024),¹³ whereas dealers maintain sole control of the cocaine and basuco markets due to their continuing illegal status. Figure 15 shows the posterior distribution of the estimated government tax revenue from the "safe" consumers, with a median value of approximately \$121.5 million USD and a 95% credible interval of approximately (120, 123) million USD. The posterior distribution is derived from a tax of approximately US¢39 per marijuana joint (calculated as the average price of US¢41 minus the tax-free price of US¢2) and the predicted monthly number of marijuana joints consumed by individuals in this cluster,

¹³For instance, the size of the black market for cigarettes in Colombia is 34% (see the study "Consumo de cigarrillos ilegales Colombia" 2022). Similarly, 1 out 3 marijuana consumers in Uruguay reports obtaining marijuana from an illicit provider after legalization.

Figure 13: Density plot of equivalent variation following a price change in marijuana implied by EASI system estimates from "safe" cluster (annual USD)



Notes: Full posterior density over equivalent variation in 2019 USD\$ after a 50% decrease in the price of marijuana and complete access to dealers following legalization of marijuana. Dashed line represents median of chains, dotted line provides the 95% HPD for each parameter, and a solid line at 0 is drawn for reference. Single chain run keeping 10000 draws after a burn-in window of 5000 iterations, discarding every 10 draws.

again considering expansion factors.

Additionally, Figure 16 shows that dealers would face a median revenue loss of \$127 million USD from the "safe" consumers, the 95% credible interval is (-129, -125) million USD (similar figures for marijuana profits that subtract marginal cost are provided in Figure B.7 in the Appendix B). In order to make up for such losses after legalization, drug dealers will need the total number of drug users to increase. The annual weighted average expenditure in drugs post-legalization is estimated to be approximately \$157 USD (using the fraction of expansion factor over the sum of total users as weights). Based on this value, we can calculate the required number of average users required to offset a revenue change equal to the one found in Figure 16. This provides a full posterior distribution over the number of required users given in each price scenario. Figure 17 showcases that drug dealers would need an approximately 130% increase in the number of users spending at the annual average rate of \$157 USD to offset the \$127 million USD total revenue decrease. This corresponds to approximately 825 thousand new users, which would imply a jump in the regular use rate from 2.5% to 5.8% of Colombians within 12 and 65 years of age. No state or country in the world has exhibited such an increase following legalization (Anderson and Rees, 2023). The estimated increase in Colombia would be approximately closer to 30% after legalization (Ramírez-Hassan et al., 2023), which is similar to the figures found in the United States after legalization in different states (Anderson and Rees, 2023).

Table 5 summarizes the point estimates and credibility intervals of the policy-relevant quantities across all legalization price scenarios considered. We see that the magnitude and sign of the effect on consumer welfare as measured by the EV depends on the price change, with price decreases having a larger compensating

Figure 14: Shares of predicted total expenditure on drugs in Colombia by age groups under a legalization policy



Notes: Total drug market expenditure in Colombia as predicted by the counterfactual quantities from a 50% decrease in the price of marijuana, and pressuming full access to a dealer post-legalization. We use the average exchange rate in 2019 (COP/USD 3,274) to transform to US dollars. Total size of the market after implementing the policy is estimated to be 228 million USD.

Figure 15: Density plot of government revenue following a price change in marijuana implied by EASI system estimates from "safe" cluster (annual USD million)



Notes: Full posterior density over total annual government revenue given in millions of 2019 USD\$ after a 50% decrease in the price of marijuana and complete access to dealers following legalization of marijuana. Government is assumed to keep 66% of the legal market post-legalization minus the marginal cost of production and delivery. Dashed line represents median of chains, dotted line provides the 95% HPD for each parameter, and a solid line at 0 is drawn for reference. Single chain run keeping 10000 draws after a burn-in window of 5000 iterations, discarding every 10 draws.

Figure 16: Density plot of change in dealer revenue following a price change in marijuana as implied by EASI system estimates from "safe" cluster (annual USD million)



Notes: Full posterior density over change in total annual dealer revenue given in millions of 2019 USD\$ after a 50% decrease in the price of marijuana and complete access to dealers following legalization of marijuana. Dealers are assumed to keep control of 34% of the legal market post-legalization and 100% control of the cocaine and basuco markets. Dashed line represents median of chains, dotted line provides the 95% HPD for each parameter, and a solid line at 0 is drawn for reference. Single chain run keeping 10000 draws after a burn-in window of 5000 iterations, discarding every 10 draws.

Figure 17: Density plot of percentage change in number of users required to offset dealer revenue change following a price change in marijuana as implied by EASI system estimates from "safe" cluster



Notes: Full posterior density over the percentage change in the number of users required to offset the total change in annual dealer revenue after a 50% decrease in the price of marijuana and complete access to dealers following legalization of marijuana. Dealers are assumed to keep control of 34% of the legal market post-legalization and 100% control of the cocaine and basuco markets. Dashed line represents median of chains, dotted line provides the 95% HPD for each parameter, and a solid line at 0 is drawn for reference. Single chain run keeping 10000 draws after a burn-in window of 5000 iterations, discarding every 10 draws.

effect on consumers compared to the unlikely price increase. On the other hand, the estimated revenue collected by the government and losses experienced by the dealers remains consistent across the scenarios, which reflects that the largest portion of the policy effect can be explained by the large loss to marijuana market shares experienced by dealers. In summary, a legalization policy applied to the Colombian context is estimated to increase marijuana consumption, increase welfare for consumers through standardized pricing and access, and reallocate considerable revenue sources to local governments from illegal drug dealers. In this way, the policy can decrease drug profitability and disincentivize the use of violence to control the black market, which is the current a large source of violent crime in Colombia.

Scenario		Policy Quantity			
Marijuana Price Change	Equivalent Variation (USD\$)	Government Revenue (Millions USD\$)	Dealer Revenue Change (Millions USD\$)	Users for Revenue Offset (% change)	
50% decrease	363.11 (337.70, 373.85)	$121.14 \\ (119.93, 122.50)$	-126.76 (-128.36, -124.38)	$\frac{126.98\%}{(121.69\%, 130.68\%)}$	
90% decrease	3204.33 (2801.66, 3394.66)	95.01 (91.90, 98.60)	-122.80 (-129.22, -106.50)	$\frac{118.32\%}{(88.69\%, 132.71\%)}$	
25% increase	-73.17 (-75.91, -68.76)	125.26 (124.82, 125.67)	-127.96 (-128.41, -127.45)	129.73% (128.55%, 130.79%)	

 Table 5: Bayesian point estimates and credible intervals of key policy summaries post-legalization

Notes: Key policy quantities calculated in 2019 USD\$ after a 50% decrease in the price of marijuana and complete access to dealers following legalization of marijuana. While consumer welfare depends on the sign of the price change, the estimated elasticites and legalization effort imply there is always a gain for the government and a loss for suppliers.

6 Policy recommendations and Concluding remarks

This paper models the joint demand for illicit drugs in Colombia, introducing a Gaussian mixture of endogenous EASI demand systems estimated via Bayesian methods. We provide evidence that unobserved heterogeneity is a key driver of drug demand, and using our data-driven cluster assignment, we simultaneously classify individuals into either a "safe" or "addict" consumer segment and estimate the drug demand behaviour of each segment. We control for both demand- and supply-based endogenous sources of consumer price variation using as instruments geo-referenced distance-weighted averages of drug-related captures and elicited prices. Tailoring the priors to suit the setting of structural demand modeling and to take full advantage of the variability in instruments, our Bayesian results are able to provide accurate estimates of EASI coefficients and their demand implications. In particular, the results of the "safe" or recreational cluster of consumers provide accurate descriptions of drug demand patterns that represent over 550 thousand consumers across Colombia.

The framework emphasizes the importance of modeling drug demand jointly, which is not usually available given data limitations in other sources. This importance is reflected in our estimates, where complementarity and substitution effects between drugs arise. Specifically, results for our preferred specification suggest that marijuana and cocaine are complementary in an asymmetric way, such that increases to marijuana prices decrease both marijuana and cocaine consumption, but increases in cocaine price only have sizable effects on the consumption of cocaine leaving marijuana consumption statistically unchanged. Basuco is instead found to be an inferior substitute for cocaine, though largely unrelated to marijuana. Additionally, our estimates provide a good fit to the implied Engel curves in the data, showcasing the importance of accounting unobserved heterogeneity and price endogeneity to model drug demand in the Colombian setting.

Finally, we used our estimates to evaluate potential effects of a marijuana legalization policies based on different price scenarios the policy could entail. Given Colombia's drug production structure and previous experiences in legalization in developing countries, the most likely scenario of a 50% decrease in the price of marijuana creates sizable gains for consumers and the government as taxing legal providers of marijuana, with heavy losses incurred by actual illegal drug suppliers. These losses account for the fact that an illegal market of marijuana will continue existing alongside the legal purchasing system, but at a greatly reduced size compared to pre-legalization. Specifically, estimates suggest that only for the recreational consumer segment the revenue gains for the government will be close to \$120 million USD, with suppliers losing upwards of \$127 million USD in revenue. These results suggest that the profitability of the illicit drug market would decrease, and consequently, reduced incentives to control the black market would lead to a decrease in violent crimes associated with local drug trafficking. In addition, the estimated unit elasticity of marijuana and cocaine in Colombia implies that a legalization policy resulting in a 50% decrease in marijuana prices would keep the total size of the drug market largely unchanged, shifting from \$226.3 million USD to an estimated \$228.0 million USD post-legalization. This would come at the cost of higher consumption levels among existing regular users and a higher likelihood of attracting new consumers, as suggested by the literature on the effects of marijuana legalization. Nevertheless, we find that these new consumers would not considerably compensate for the lost income of drug dealers.

Given the largely mixed effects of marijuana consumption on both consumer health and job market outcomes found in the literature, our results imply that while policy makers would clearly benefit from a legalization policy and dealers would be clearly negatively impacted, the effects on consumers are not clear cut. On one hand, while consumption of marijuana is expected to almost double for the representative agent (given the 50% price decrease at unit-elasticity), this is valued by consumers at approximately \$363 annual USD of utility-equivalent expenditure, which represents 100% of current total drug expenditure and around 12% of the yearly minimum wage in 2019. On the other hand, the increased consumption would have additional heterogeneous indirect effects on public health, productivity, educational attainment, etc. Therefore, it is key that a legalization policy is accompanied by additional targeted policy efforts for each population segment, particularly for individuals in the "addict" and "at-risk" groups.

References

- Anderson, D. M. and Rees, D. I. (2023). The public health effects of legalizing marijuana. Journal of Economic Literature, 61(1):86–143.
- Aristei, D. and Pieroni, L. (2010). Habits, complementarities and heterogeneity in alcohol and tobacco demand: A multivariate dynamic model. Oxford Bulletin of Economics and Statistics, 72(4):428–457.
- Banks, J., Blundell, R., and Lewbel, A. (1997). Quadratic Engel curves and consumer demand. Review of Economics and Statistics, 79(4):527–539.
- BanRep (2019). Banco de la República de Colombia, Estadísticas Económicas. https://suameca.banrep.gov.co/estadisticas-economicas/reporte-oac.html?path=%2FTrabajo%20CIE%2FA_preliminar_produccion%2FUsuario_final%2F4.Sector_Externo_tasas_de_cambio_y_derivados%2F1.%20Tasas%20de%20cambio%2F1.%20Tasa%20de%20cambio%20del%20peso%20colombiano%20por%20USD(TRM)%2F1.%20Tasa%20de%20Cambio%20USD%5C%2FCOP%2F1.Promedio%20anual%20y%20fin%20de%20a%C3%B1o_Tasa%20Representativa%20Mercado%20(TRM). Promedio anual de la Tasa Representativa del Mercado (TRM). [Accessed: February 28, 2025.].
- Becker, G. S., Murphy, K. M., and Grossman, M. (2006). The market for illegal goods: the case of drugs. Journal of Political Economy, 114(1):38–60.
- Bertail, P. and Caillavet, F. (2008). Fruit and vegetable consumption patterns: a segmentation approach. American Journal of Agricultural Economics, 90(3):827–842.
- Blundell, R., Chen, X., and Kristensen, D. (2007). Semi-nonparametric IV estimation of shape-invariant Engel curves. *Econometrica*, 75(6):1613–1669.
- Blundell, R., Pashardes, P., and Weber, G. (1993). What do we learn about consumer demand patterns from micro data? *American Economic Review*, pages 570–597.
- Bokhari, F. A. S. and Mariuzzo, F. (2018). Demand estimation and merger simulations for drugs: Logits v. AIDS. International Journal of Industrial Organization, 61:653–685.
- Bonnet, C. and Réquillart, V. (2013). Tax incidence with strategic firms in the soft drink market. *Journal of Public Economics*, 106:77–88.
- Bretteville-Jensen, A. L., Melberg, H. O., and Jones, A. M. (2008). Sequential patterns of drug use initiation: Can we believe in the gateway theory? *The BE Journal of Economic Analysis & Policy*, 8(2).
- Brinkman, J. and Mok-Lamme, D. (2019). Not in my backyard? not so fast. the effect of marijuana legalization on neighborhood crime. *Regional Science and Urban Economics*, 78:103460.
- Burkhardt, J. and Goemans, C. (2019). The short-run effects of marijuana dispensary openings on local crime. *The Annals of Regional Science*, 63(1):163–189.
- Caulkins, J. P., Kilmer, B., Kleiman, M. A., MacCoun, R. J., Midgette, G., Oglesby, P., Pacula, R. L., and Reuter, P. H. (2015). Options and Issues Regarding Marijuana Legalization. Rand Corporation.
- Chu, Y.-W. L. and Townsend, W. (2019). Joint culpability: the effects of medical marijuana laws on crime. Journal of economic behavior & organization, 159:502–525.

- Cleveland, W. S., Grosse, E., and Shyu, W. M. (2017). Local regression models. In *Statistical Models in S*, pages 309–376. Routledge.
- Davis, A. J., Geisler, K. R., and Nichols, M. W. (2016). The price elasticity of marijuana demand: Evidence from crowd-sourced transaction data. *Empirical Economics*, 50.
- Deaton, A. and Muellbauer, J. (1980). An almost ideal demand system. *American Economic Review*, 70(3):312–326.
- DeSimone, J. (1998). Is marijuana a gateway drug? Eastern Economic Journal, 24(2):149–164.
- Deza, M. (2015). Is there a stepping stone effect in drug use? separating state dependence from unobserved heterogeneity within and between illicit drugs. *Journal of Econometrics*, 184(1):193–207.
- Deza, M. (2023). Unemployment, Alcohol and Tobacco Use: Separating State Dependence from Unobserved. Technical report, National Bureau of Economic Research.
- Dragone, D., Prarolo, G., Vanin, P., and Zanella, G. (2019). Crime and the legalization of recreational marijuana. Journal of economic behavior & organization, 159:488–501.
- Duffy, M. (2003). Advertising and food, drink and tobacco consumption in the United Kingdom: a dynamic demand system. Agricultural Economics, 28(1):51–70.
- Embree, B. G. and Whitehead, P. C. (1993). Validity and reliability of self-reported drinking behavior: dealing with the problem of response bias. *Journal of Studies on Alcohol*, 54(3):334–344.
- Fadnes, L. T., Taube, A., and Tylleskär, T. (2009). How to identify information bias due to self-reporting in epidemiological research. *Internet Journal of Epidemiology*, 7(2):28–38.
- Fergusson, D. M., Boden, J. M., and Horwood, L. J. (2006). Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. *Addiction*, 101(4):556–569.
- Frühwirth-Schnatter, S. (2006). Finite mixture and Markov switching models. Springer.
- Galenianos, M. and Gavazza, A. (2017). A structural model of the retail market for illicit drugs. American Economic Review, 107(3):858–896.
- Gallet, C. A. (2014). Can price get the monkey off our back? a meta-analysis of illicit drug demand. Health Economics (United Kingdom), 23.
- Gavrilova, E., Kamada, T., and Zoutman, F. (2019). Is legal pot crippling mexican drug trafficking organisations? the effect of medical marijuana laws on us crime. *The Economic Journal*, 129(617):375–407.
- Hall, W. and Lynskey, M. (2016). Evaluating the public health impacts of legalizing recreational cannabis use in the United States. *Addiction*, 111(10):1764–1773.
- Huber III, A., Newman, R., and LaFave, D. (2016). Cannabis control and crime: Medicinal use, depenalization and the war on drugs. *The BE journal of economic analysis & policy*, 16(4):20150167.
- Jacobi, L., Nghiem, N., Ramírez-Hassan, A., and Blakely, T. (2021). Food Price Elasticities for Policy Interventions: Estimates from a Virtual Supermarket Experiment in a Multistage Demand Analysis with (Expert) Prior Information. *Economic Record*, 97(319):457–490.

- Jacobi, L. and Sovinsky, M. (2016). Marijuana on main street? estimating demand in markets with limited access. American Economic Review, 106(8):2009–2045.
- Jofre-Bonet, M. and Petry, N. M. (2008). Trading apples for oranges?: Results of an experiment on the effects of heroin and cocaine price changes on addicts' polydrug use. *Journal of Economic Behavior & Organization*, 66(2):281–311.
- Johnson, T. and Fendrich, M. (2005). Modeling sources of self-report bias in a survey of drug use epidemiology. Annals of Epidemiology, 15(5):381–389.
- Jorgensen, C. and Wells, J. (2021). Is marijuana really a gateway drug? a nationally representative test of the marijuana gateway hypothesis using a propensity score matching design. *Journal of Experimental Criminology*, pages 1–18.
- Kandel, D. (1975). Stages in adolescent involvement in drug use. Science, 190(4217):912–914.
- Kass, R. E. and Raftery, A. E. (1995). Bayes factors. Journal of the american statistical association, 90(430):773–795.
- Kasteridis, P., Yen, S. T., and Fang, C. (2011). Bayesian estimation of a censored linear almost ideal demand system: Food demand in Pakistan. American Journal of Agricultural Economics, 93(5):1374–1390.
- Kehlbacher, A., Srinivasan, C., McCloy, R., and Tiffin, R. (2020). Modelling preference heterogeneity using a Bayesian finite mixture of Almost Ideal Demand Systems. *European Review of Agricultural Economics*, 47(3):933–970.
- Lacruz, A. and Molina, J. (2009). Alcohol demand among young people in Spain: An addictive QUAIDS. *Empirical Economics*, 36:515–530.
- Lewbel, A. and Pendakur, K. (2009). Tricks with Hicks: The EASI demand system. American Economic Review, 99(3):827–863.
- Lynskey, M. and Agrawal, A. (2018). Denise Kandel's classic work on the gateway sequence of drug acquisition. Addiction, 113(10):1927–1932.
- Melberg, H. O., Jones, A. M., and Bretteville-Jensen, A. L. (2010). Is cannabis a gateway to hard drugs? *Empirical Economics*, 38:583–603.
- Moro, D. and Sckokai, P. (2000). Heterogeneous preferences in household food consumption in Italy. *European Review of Agricultural Economics*, 27(3):305–323.
- Plúas-López, A. (2024). Beyond Legalization: Access and Use of (Non-) Drug-Trafficking Marijuana. Technical report, CUNEF Universidad.
- Puerta-Cuartas, A. and Ramírez-Hassan, A. (2024). A spatial one-sided error model to identify where unarrested criminals live. *Economic Modelling*, page 106929.
- Queirolo, R., Rossel, C., Álvarez, E., and Repetto, L. (2019). Why uruguay legalized marijuana? the open window of public insecurity. *Addiction*, 114(7):1313–1321.

- Ramírez-Hassan, A. (2021). Bayesian estimation of the exact affine Stone index demand system: Replicating the Lewbel and Pendakur (2009) results. *Journal of Applied Econometrics*, 36(4):484–491.
- Ramírez-Hassan, A. and López-Vera, A. (2024). Welfare implications of a tax on electricity: A semiparametric specification of the incomplete EASI demand system. *Energy Economics*, page 107389.
- Ramírez-Hassan, A., Gomez, C., Velasquez, S., and Tangarife, K. (2023). Marijuana on main streets? the story continues in colombia: An endogenous three-part model. arXiv preprint arXiv:2306.10031.
- Riley, S., Vellios, N., and van Walbeek, C. (2020). An economic analysis of the demand for cannabis: Some results from South Africa. *Drugs: Education, Prevention and Policy*, 27.
- Rosenman, R., Tennekoon, V., and Hill, L. G. (2011). Measuring bias in self-reported data. International Journal of Behavioural and Healthcare Research, 2(4):320–332.
- Steenkamp, J.-B. E. M., de Jong, M. G., and Baumgartner, H. (2010). Socially desirable response tendencies in survey research. *Journal of Marketing Research*, 47(2):199–214.
- Sukharomana, R. and Chang, C. L. (2017). Demand for narcotics in thailand, with policy implications. Journal of Reviews on Global Economics, 6.
- Tauchmann, H., Lenz, S., Requate, T., and Schmidt, C. M. (2013). Tobacco and alcohol: complements or substitutes? a structural model approach to insufficient price variation in individual-level data. *Empirical Economics*, 45:539–566.
- Thies, C. F. and Register, C. A. (1993). Decriminalization of marijuana and the demand for alcohol, marijuana and cocaine. *Social Science Journal*, 30(4):385–399.
- Tiffin, R. and Arnoult, M. (2010). The demand for a healthy diet: estimating the almost ideal demand system with infrequency of purchase. *European Review of Agricultural Economics*, 37(4):501–521.
- UNODC (2021). World Drug Report. Technical report, United Nations publication.
- UNODC (2023). World Drug Report. Technical report, United Nations publication.
- van Ours, J. C. (2003). Is cannabis a stepping-stone for cocaine? Journal of Health Economics, 22(4):539–554.
- van Ours, J. C. (2006). Dynamics in the use of drugs. Health Economics, 15(12):1283–1294.
- Vélez-Torres, I., Hurtado, D., and Bueno, B. (2021). Medicinal Marijuana, Inc.: A critique on the market-led legalization of cannabis and the criminalization of rural livelihoods in Colombia. *Critical Criminology*, 29:505–526.
- von Haefen, R. H., Phaneuf, D. J., and Parsons, G. R. (2004). Estimation and welfare analysis with large demand systems. *Journal of Business & Economic Statistics*, 22(2):194–205.
- Wu, G., Boateng, F. D., and Lang, X. (2020). The spillover effect of recreational marijuana legalization on crime: evidence from neighboring states of colorado and washington state. *Journal of Drug Issues*, 50(4):392–409.

- Wu, G., Li, Y., and Lang, X. E. (2022). Effects of recreational marijuana legalization on clearance rates for violent crimes: Evidence from oregon. *International Journal of Drug Policy*, 100:103528.
- Zhen, C., Finkelstein, E. A., Nonnemaker, J. M., Karns, S. A., and Todd, J. E. (2014). Predicting the effects of sugar-sweetened beverage taxes on food and beverage demand in a large demand system. *American Journal of Agricultural Economics*, 96(1):1–25.

A Computational Implementation Details

An alternative representation that proves useful for the derivations and computational implementation of the system of EASI equation with endogeneity is as follows. Let

$$\check{\boldsymbol{\beta}}^{(1)} \coloneqq \begin{bmatrix} \boldsymbol{\beta}_1^{(1)} & \cdots & \boldsymbol{\beta}_s^{(1)} \end{bmatrix} = \begin{bmatrix} \boldsymbol{b}_0^{\top} \\ \vdots \\ \boldsymbol{b}_R^{\top} \\ \boldsymbol{C}^{\top} \\ \boldsymbol{D}^{\top} \end{bmatrix} \quad \text{and} \quad \check{\boldsymbol{\beta}}^{(2)} \coloneqq \begin{bmatrix} \boldsymbol{A}_0 \\ \vdots \\ \boldsymbol{A}_M \\ \boldsymbol{B}, \end{bmatrix}$$

such that we can express (5) in row vectors instead of column vectors to obtain

$$\boldsymbol{w}_{i}^{*\top} = \boldsymbol{x}_{i}^{\top} \boldsymbol{\check{\beta}}^{(1)} + \boldsymbol{p}_{i}^{*\top} \boldsymbol{\check{\beta}}^{(2)} + \boldsymbol{\varepsilon}_{i}^{\top}.$$
(A.1)

Stacking (A.1) across individuals gives a matrix representation of the EASI equations with endogeneity:

$$\mathbf{W}^* = \mathbf{X}\check{\boldsymbol{\beta}}^{(1)} + \mathbf{P}^*\check{\boldsymbol{\beta}}^{(2)} + \boldsymbol{\varepsilon} = \mathbf{F}\check{\boldsymbol{\beta}} + \boldsymbol{\varepsilon}, \qquad (A.2)$$

where $\mathbf{F} \coloneqq [\mathbf{X}, \mathbf{P}^*], \, \check{\boldsymbol{\beta}} \coloneqq [\check{\boldsymbol{\beta}}^{(1)\top}, \check{\boldsymbol{\beta}}^{(2)\top}]^{\top}$, and we define

$$\mathbf{W}_{(n\times s)}^{*} \coloneqq \begin{bmatrix} \boldsymbol{w}_{1}^{*\top} \\ \vdots \\ \boldsymbol{w}_{n}^{*\top} \end{bmatrix}, \quad \mathbf{X}_{(n\times(1+R+M+M_{y}))} \coloneqq \begin{bmatrix} \boldsymbol{x}_{1}^{\top} \\ \vdots \\ \boldsymbol{x}_{n}^{\top} \end{bmatrix}, \quad \mathbf{P}^{*}_{(n\times s(M_{p}+2))} \coloneqq \begin{bmatrix} \boldsymbol{p}_{1}^{*\top} \\ \vdots \\ \boldsymbol{p}_{n}^{*\top} \end{bmatrix} \quad \text{and} \quad \boldsymbol{\varepsilon}_{(n\times s)} \coloneqq \begin{bmatrix} \varepsilon_{1}^{\top} \\ \vdots \\ \varepsilon_{n}^{\top} \end{bmatrix}.$$

This is a more efficient matrix representation memory-wise compared to that provided in (6), in the sense that \mathbf{X} and \mathbf{P}^* are data matrices with no padding structure in contrast to the rows of F_1, \ldots, F_n . We use these representations in our implementations of the Bayesian sampling algorithms outlined above. Additionally, we can relate the coefficients obtained by both representations since $\operatorname{vec}(\check{\boldsymbol{\beta}}^{(1)}) = \boldsymbol{\beta}^{(1)}$ and $\operatorname{vec}(\check{\boldsymbol{\beta}}^{(2)\top}) = (I_{M_p+2} \otimes \boldsymbol{D}_s)\boldsymbol{\beta}^{(2)}$. The corresponding representation for the first stage equation is

$$\mathbf{P}^* = \mathbf{G}\check{\boldsymbol{\gamma}} + \mathbf{u},\tag{A.3}$$

where $\check{\gamma} := [\check{\gamma}_1, \dots, \check{\gamma}_s]$, and we define similar matrices for the first-stage:

$$\mathbf{G}_{(n imes (1+R+M+M_y+\ell))} \coloneqq egin{bmatrix} oldsymbol{x}_1^ op & oldsymbol{z}_1^ op \\ oldsymbol{x}_n^ op & oldsymbol{z}_n^ op \end{bmatrix} & ext{and} \quad oldsymbol{u} \ (n imes s(M_p+2)) \coloneqq egin{bmatrix} oldsymbol{u}_1^ op \\ oldsymbol{z}_n^ op & oldsymbol{z}_n^ op \end{bmatrix}.$$

An additional benefit of this representation — and the motivation behind our derivation — is that we can more efficiently compute sums across units i where each element is of the form $\mathbf{F}_i^{\top} \mathbf{S} \mathbf{F}_i$ or $\mathbf{F}_i \mathbf{S} \mathbf{w}_i^*$, for any $s \times s$ symmetric matrix \mathbf{S} (where \mathbf{F}_i is as defined in Eq. 7 and has s rows). Specifically, one can easily check the following equalities hold:

$$\sum_{i=1}^{n} \boldsymbol{F}_{i}^{\top} \boldsymbol{S} \boldsymbol{F}_{i} = \boldsymbol{S} \otimes \left(\boldsymbol{F}^{\top} \boldsymbol{F} \right) ,$$

$$\sum_{i=1}^{n} \boldsymbol{F}_{i}^{\top} \boldsymbol{S} \boldsymbol{w}_{i}^{*} = \left[\boldsymbol{I}_{s} \otimes \left(\boldsymbol{F}^{\top} \boldsymbol{W}^{*} \right) \right] \operatorname{vec}(\boldsymbol{S}) .$$
(A.4)

In standard packages, these expressions create bottlenecks for computation as they are computed within a loop over n instead of using matrix operations. As the sample size n is large in microeconomic datasets, the memory taken by the stacked padded F_i can also be much larger than that of F if not stored as sparse, and computations need to be adjusted to take this into account. By using simple matrix operations, we achieve both speed and potential memory gains with respect to the commonly implemented non-sparse approaches.

Covariate	Dependent	Dependent Variable		
	Relative price marijuana	Relative price cocaine		
	Included instruments			
Constant	-0.997	-1.419		
Constant	(-1.311, -0.684)	(-1.846, -1.020)		
Deploy Preserves	0.051	0.094		
Dealer r resence	(-0.012, 0.111)	(0.014, 0.179)		
Modium Diale	-0.040	-0.148		
Medium Kisk	(-0.281, 0.201)	(-0.469, 0.177)		
High Dick	-0.050	-0.183		
Tilgii Risk	(-0.258, 0.156)	(-0.452, 0.089)		
Consumer in notwork	-0.150	-0.131		
Consumer in network	(-0.275, -0.024)	(-0.292, 0.039)		
Famala	-0.017	0.017		
remate	(-0.087, 0.053)	(-0.080, 0.111)		
Both parents at home	-0.030	-0.065		
Doth parents at nome	(-0.119, 0.059)	(-0.183, 0.052)		
Modicinal marijuana producta	-0.015	-0.055		
Medicinal marijuana products	(-0.077, 0.045)	(-0.137, 0.027)		
Good physical health	-0.029	-0.012		
Good physical nearth	(-0.107, 0.047)	(-0.113, 0.090)		
Good mental health	0.008	0.002		

B Additional Results

Table B.1:	Bayesian	estimates	of first-stage	coefficients
------------	----------	-----------	----------------	--------------

	(-0.058, 0.075)	(-0.088, 0.092)
	0.015	0.037
Years of education	(0.006, 0.024)	(0.024, 0.050)
	-0.029	-0.040
Head of household	(-0.098, 0.041)	(-0.132, 0.052)
	0.266	0.290
Medium SES	(0.197, 0.337)	(0.197, 0.383)
	-0.302	0.422
High SES	(-0.441, -0.162)	(0.236, 0.606)
TT 1.	-0.043	-0.000003
Working status	(-0.109, 0.023)	(-0.086878, 0.086823)
	0.004	0.0003
Age minus 30	(-0.001, 0.010)	(-0.0065, 0.0073)
	0.032	0.059
Codependent substance use	(-0.052, 0.116)	(-0.052, 0.167)
Ъ. т	-0.426	-0.433
Metropolitan area	(-0.494, -0.358)	(-0.522, -0.344)
m	-0.005	-0.002
1 ime using marijuana	(-0.010, 0.000)	(-0.010, 0.005)
T:	0.003	0.003
Time using cocaine	(-0.002, 0.008)	(-0.004, 0.010)
m· · 1	-0.002	-0.004
Time using basuco	(-0.008, 0.005)	(-0.012, 0.005)
W f	0.011	0.022
was onered marijuana	(-0.089, 0.113)	(-0.110, 0.163)
Was afferred accoinc	0.052	0.066
was onered cocame	(-0.021, 0.126)	(-0.035, 0.165)
W	-0.013	-0.028
was offered basuco	(-0.100, 0.069)	(-0.141, 0.083)
Obtained manifusne apline	0.103	0.193
Obtained marijuana online	(-0.002, 0.209)	(0.055, 0.333)
Obtained manifusne in parson	-0.006	0.033
Obtained marijuana in person	(-0.083, 0.074)	(-0.074, 0.140)
Obtained manifester through friends	-0.010	0.021
Obtained marijuana through mends	(-0.088, 0.068)	(-0.082, 0.124)
Obtained manifugne other / missing	-0.030	-0.062
Obtained marijuana other / missing	(-0.207, 0.141)	(-0.296, 0.168)
Obtained accesing onling	0.062	0.378
Obtained cocame onnine	(-0.134, 0.258)	(0.115, 0.637)
Obtained accesing in person	-0.017	-0.180
Obtained cotaine in person	(-0.130, 0.096)	(-0.330, -0.031)
Obtained agains through friends	0.039	-0.090
Obtained cocame through friends	(-0.069, 0.146)	(-0.233, 0.054)
Obtained cocaine other / missing	0.305	1.501
Obtained cocame other / missing		

	(-0.283, 0.898)	(0.726, 2.284)	
Obtained basues only	0.250	-0.301	
Obtained basuco online	(-0.784, 1.286)	(-1.680, 1.090)	
014 : 11 :	-0.042	0.139	
Obtained basuco in person	(-0.240, 0.156)	(-0.116, 0.398)	
	-0.160	0.058	
Obtained basuco through friends	(-0.394, 0.072)	(-0.241, 0.367)	
T 1. ().	-0.187	-0.026	
Indirect utility (y)	(-0.257, -0.117)	(-0.117, 0.066)	
T 1	0.023	-0.002	
Indirect utility ²	(0.014, 0.032)	(-0.015, 0.010)	
т. н	-0.005	-0.003	
Indirect utility ⁵	(-0.008, -0.002)	(-0.007, 0.002)	
Еж	ccluded instruments		
$\log(1 + Drug \text{ captures})$	0.063	0.125	
$\log(1 + D) \log (a)$	(0.041, 0.085)	(0.095, 0.155)	
Dictories weighted price of marijuana	0.0003	-0.00001	
Distance-weighted price of marijuana	(0.0003, 0.0003)	(-0.00003, 0.00002)	
	0.000004	0.000009	
Distance-weighted price of cocame	(-0.000002, 0.000011)	(0.000000, 0.000017)	
$\log(1 + \text{Drug captures}) \times y$	-0.006	0.001	
	(-0.016, 0.004)	(-0.012, 0.014)	
	0.00007	0.000007	
Distance-weighted price of marijuana $\times y$	(0.00006, 0.00008)	(-0.000008, 0.000022)	
Distance maintain of a single of	0.0000007	-0.0000007	
Distance-weighted price of cocaline $\times y$	(-0.0000023, 0.0000037)	(-0.0000047, 0.0000032)	
Covariate	Dependent Variable		
	Relative price marijuana × y	Relative price cocaine $\times y$	
In	cluded instruments		
Constant	-0.003	-0.078	
Constant	(-0.436, 0.429)	(-0.555, 0.382)	
Dealer Progence	-0.019	0.051	
Dealer 1 resence	(-0.126, 0.088)	(-0.075, 0.177)	
Modium Pisk	-0.034	-0.034	
WEXHUILI IVISK	(-0.361, 0.299)	(-0.387, 0.323)	
High Disk	-0.076	-0.058	
IIIgii AISK	(-0.366, 0.216)	(-0.369, 0.256)	
Congumen in natural	-0.130	0.059	
Consumer in network	(-0.327, 0.069)	(-0.173, 0.285)	
	-0.032	-0.067	
remaie	(-0.149, 0.085)	(-0.207, 0.070)	
	-0.058	-0.084	
Both parents at home			

	(-0.194, 0.076)	(-0.245, 0.073)
Madiainal manijuana producta	-0.029	0.042
Medicinal marijuana products	(-0.137, 0.075)	(-0.085, 0.166)
Coord relational hereith	0.048	-0.079
Good physical nearth	(-0.075, 0.173)	(-0.227, 0.072)
Card mental bask	-0.045	0.121
Good mental nealth	(-0.153, 0.066)	(-0.008, 0.254)
Very of education	0.013	0.025
fears of education	(-0.006, 0.030)	(0.003, 0.047)
	-0.072	-0.035
Head of household	(-0.187, 0.042)	(-0.177, 0.102)
Madiana GEC	-0.069	0.025
Medium SES	(-0.187, 0.048)	(-0.121, 0.160)
	0.226	-0.081
HIGH SES	(0.029, 0.430)	(-0.304, 0.143)
TT 7 1 •	-0.004	0.051
Working status	(-0.112, 0.103)	(-0.078, 0.181)
A : 20	0.014	0.00001
Age minus 30	(0.002, 0.024)	(-0.01493, 0.01387)
	0.023	-0.027
Codependent substance use	(-0.109, 0.159)	(-0.187, 0.128)
	-0.016	-0.148
Metropolitan area	(-0.129, 0.101)	(-0.285, -0.007)
m· · ·	-0.014	-0.008
Time using marijuana	(-0.025, -0.003)	(-0.021, 0.006)
m· · ·	-0.002	-0.015
Time using cocaine	(-0.013, 0.009)	(-0.028, -0.001)
	0.006	0.010
Time using basuco	(-0.009, 0.020)	(-0.008, 0.028)
	0.002	0.015
Was offered marijuana	(-0.154, 0.157)	(-0.165, 0.193)
	0.047	0.016
Was offered cocaine	(-0.075, 0.174)	(-0.130, 0.161)
	0.033	0.003
Was offered basuco	(-0.096, 0.163)	(-0.145, 0.155)
	-0.052	0.201
Obtained marijuana online	(-0.209, 0.114)	(0.016, 0.394)
	-0.106	-0.008
Obtained marijuana in person	(-0.235, 0.021)	(-0.161, 0.139)
	-0.081	0.065
Obtained marijuana through friends	(-0.204, 0.040)	(-0.083, 0.207)
	-0.178	0.253
Obtained marijuana other / missing	(-0.443, 0.097)	(-0.054, 0.560)
	0.026	0.058
Obtained cocaine online		

	(-0.220, 0.279)	(-0.206, 0.335)
Obtained accesing in parson	0.077	-0.240
Obtained cocame in person	(-0.088, 0.241)	(-0.431, -0.059)
Obtained accessing through failer de	0.060	-0.119
Obtained cocame through mends	(-0.096, 0.218)	$\left(-0.299, 0.057 ight)$
Obtained accessing at here / missing	-0.935	1.182
Obtained cocame other / missing	(-1.648, -0.214)	(0.468, 1.956)
Obtained harves online	0.222	-0.299
Obtained basuco onine	(-0.997, 1.425)	(-1.481, 0.886)
Obtained basues in parson	-0.111	0.141
Obtained basuco in person	(-0.360, 0.146)	(-0.125, 0.415)
Obtained basues through friends	0.262	-0.222
Obtained basico through mends	(-0.022, 0.551)	(-0.523, 0.077)
Indiroct utility (a)	-0.173	-0.179
maneet utility (g)	(-0.274, -0.070)	(-0.299, -0.065)
Indirect utility ²	-0.138	-0.090
induced utility	(-0.159, -0.118)	(-0.116, -0.066)
Indiroct utility ³	-0.009	-0.017
induced utility	(-0.016, -0.001)	(-0.026, -0.008)
Excl	uded instruments	
$l_{r} = (1 + D_{r})$	-0.002	0.016
$\log(1 + \text{Drug captures})$	(-0.032, 0.028)	(-0.016, 0.049)
	0.0001	-0.00009
Distance-weighted price of marijuana	(0.0001, 0.0002)	(-0.00013, -0.00005)
Distance weighted price of eccering	0.000004	0.000002
Distance-weighted price of cocame	(-0.000004, 0.000013)	(-0.000007, 0.000010)
$\log(1 + D_{\text{mus}} \text{ conturned}) \times \alpha$	-0.026	0.033
$\log(1 + Drug \text{ captures}) \times y$	(-0.039, -0.013)	(0.019, 0.048)
Distance mainted price of manifusne V of	0.0002	-0.0001
Distance-weighted price of marijuana $\times y$	(0.0002, 0.0002)	(-0.0001, -0.0001)
Distance weighted price of coasing V a	0.0000007	-0.000002
Distance-weighted price of cocallie $\times y$	(-0.0000033, 0.0000046)	(-0.000006, 0.000002)

Notes: Posterior median coefficients from the Bayesian first-stage regressions on each of the endogenous variables of the EASI system. 95% posterior quantile credibility intervals are presented underneath the coefficients. There is only one set of results as our main specification maintains homogeneous coefficients in the first stage.

Covariate	"Safe" ("Safe" Cluster		
	Share of Marijuana	Share of Cocaine		
	Exogenous			

Table B.2: Bayesian estimates of EASI coefficients across clusters

Constant	0.953	0.043
Constant	(0.907, 1.001)	$\left(-0.007, 0.093 ight)$
Declar Process	-0.005	0.004
Dealer Presence	(-0.014, 0.005)	(-0.005, 0.014)
	-0.005	0.004
Medium Risk	(-0.041, 0.032)	(-0.032, 0.041)
	0.003	-0.002
High Risk	(-0.027, 0.034)	(-0.033, 0.028)
	-0.007	0.006
Consumer in network	(-0.025, 0.012)	(-0.012, 0.025)
Freedo	0.000	0.002
Female	(-0.011, 0.010)	(-0.009, 0.013)
	0.002	-0.001
Both parents at nome	(-0.011, 0.015)	(-0.014, 0.013)
	0.004	-0.004
Medicinal marijuana products	(-0.006, 0.013)	(-0.014, 0.006)
Coord advantage la colta	-0.003	0.004
Good physical health	(-0.015, 0.009)	(-0.008, 0.016)
Card mental bask	0.001	-0.001
Good mental health	(-0.010, 0.011)	(-0.012, 0.010)
Very of education	0.000	0.000
fears of education	(-0.002, 0.001)	(-0.001, 0.002)
Head of household	0.000	0.002
fiead of household	(-0.011, 0.010)	(-0.009, 0.013)
Modium CEC	0.002	-0.001
Medium SES	(-0.008, 0.013)	(-0.013, 0.012)
High SFS	0.010	-0.008
Ingli SES	(-0.013, 0.033)	(-0.032, 0.016)
Working status	-0.003	0.002
Working status	(-0.013, 0.007)	(-0.008, 0.013)
Ago minus 30	-0.002	0.002
Age minus 50	(-0.003, -0.001)	(0.001, 0.003)
Codependent substance use	0.006	-0.006
Coupendent substance use	(-0.006, 0.018)	(-0.019, 0.006)
Metropolitan area	0.005	-0.005
Metropolitali area	(-0.005, 0.016)	(-0.017, 0.006)
Time using marijuana	0.003	-0.002
Time using marijuana	(0.002, 0.004)	(-0.003, -0.001)
Time using cocaine	0.000	0.000
	(-0.001, 0.001)	(-0.001, 0.001)
Time using basuco	-0.001	0.001
	(-0.002, 0.000)	(0.000, 0.002)
Was offered marijuana	0.006	-0.007
	(-0.010, 0.021)	(-0.021, 0.009)

Covariate	"Addict" Cluster				
Observations	1,0)69			
Relative price cocaine $\times y$	(-0.008, 0.021)	(-0.014, 0.025)			
	0.006	0.005			
Relative price marijuana $\times y$	(-0.009, 0.013)	(-0.008, 0.021)			
	0.002	0.006			
Relative price cocaine	$(-0.015 \ 0.004)$	(-0.021, 0.019)			
	-0.004	_0.001			
Relative price marijuana	(-0.004)	(-0.004)			
	0.004	_0.004			
Endogenous					
inditeet utility	(0.000, 0.001)	(-0.001, 0.001)			
Indirect utility ³	0.000	0.000			
indirect during	(-0.002, 0.004)	(-0.003, 0.004)			
Indirect utility ²	0.001	0.001			
$\frac{1}{2} (g)$	(-0.006, 0.007)	$\left(-0.005, 0.010 ight)$			
Indirect utility (u)	0.000	0.002			
Sovanice based through filends	(1.119, 1.396)	(-1.360, -1.127)			
Obtained basuco through friends	1.277	-1.245			
Obtained basileo in person	(-0.170, -0.059)	(-0.090, 0.024)			
Obtained basuco in person	-0.114	-0.032			
Obtained basiled online	(-61.668, 61.339)	$\left(-62.616, 62.290 ight)$			
Obtained basuco online	-0.612	0.120			
o stanice cocurre other / missing	(-0.360, -0.089)	(0.089, 0.362)			
Obtained cocaine other / missing	-0.225	0.225			
e stanted cookine infough filehub	(-0.918, -0.864)	(0.864, 0.918)			
Obtained cocaine through friends	-0.891	0.891			
	(-0.909, -0.842)	(0.845, 0.911)			
Obtained cocaine in person	-0.876	0.878			
	(0.813, 0.927)	(-0.928, -0.811)			
Obtained cocaine online	0.871	-0.870			
	(0.016, 0.069)	(-0.071, -0.017)			
Obtained marijuana other / missing	0.042	-0.044			
	(0.032, 0.060)	(-0.061, -0.033)			
Obtained marijuana through friends	0.046	-0.047			
	(0.027, 0.055)	(-0.056, -0.027)			
Obtained marijuana in person	0.041	-0.041			
	(0.000, 0.034)	(-0.035, 0.000)			
Obtained marijuana online	0.017	-0.017			
	(-0.004, 0.023)	(-0.024, 0.004)			
Was offered basuco	0.009	-0.010			
	(-0.020, 0.001)	(-0.002, 0.021)			
Was offered cocaine	-0.010	0.009			

	Share of Marijuana	Share of Cocaine
	Exogenous	
Constant	0.286	6.340
Constant	(-52.328, 53.268)	(-48.412, 60.330)
Dealer Procence	-1.007	-2.305
Jeaner 1 resence	(-34.590, 34.177)	(-38.548, 36.414)
Modium Bick	11.974	10.874
Medium Risk	$\left(-36.213, 61.629 ight)$	(-39.186, 60.963)
Jigh Digl	-6.132	-3.588
light Kisk	(-51.800, 40.220)	(-52.805, 44.320)
<u> </u>	-1.869	2.539
Jonsumer in network	(-49.216, 44.859)	(-47.214, 51.802)
2	-12.844	-14.108
emale	(-48.805, 24.229)	(-53.966, 25.876)
	-23.123	-24.736
Both parents at home	(-63.325, 17.750)	(-67.517, 18.437)
	5.353	7.925
Medicinal marijuana products	(-30.008, 39.526)	(-30.302, 44.349)
~	-9.401	1.902
food physical health	(-48.692, 30.096)	(-40.552, 44.496)
~	12.226	11.535
Good mental health	(-21.394, 46.615)	(-24.906, 48.869)
	6.243	5.645
lears of education	(-0.674, 12.560)	(-1.844, 12.787)
	-13.831	-18.654
lead of household	(-50.278, 22.952)	(-57.086, 20.366)
	-23.720	-23.838
Medium SES	(-63.235, 13.978)	(-64.642.15.916)
	4.255	29.499
ligh SES	$(-43\ 674\ 49\ 875)$	(-20.071, 78.260)
	9 931	14 661
Working status	$(-24\ 325\ 43\ 701)$	$(-22\ 970\ 50\ 572)$
	1 606	2 316
Age minus 30	$(-3\ 139\ 5\ 679)$	(-25247020)
	(-5.617)	(2.024, 1.020) -10.641
Codependent substance use	$(-46\ 911\ 34\ 951)$	$(-55\ 738\ 32\ 860)$
	_2 080	2 068
Metropolitan area	-2.909	2.000 (_34.840-30.913)
	(-37.143, 33.230) -2.106	_1 522
lime using marijuana	-2.100	-4.000
	(-0.020, 2.200)	(-3.041, 0.249) 2.201
Time using cocaine	-4.113	-2.301
	(-0.709, -0.587)	(-0.548, 2.200)
Time using basuco	2.899	2.100

	(-2.708, 8.394)	(-4.274, 7.403)
XX7 (f 1 ···	15.949	-2.721
was offered marijuana	(-26.390, 57.873)	(-46.761, 41.754)
W C I ·	-0.386	9.001
was offered cocaine	(-38.625, 39.271) $(-31.552, 49.5)$	
W. (* 11	7.018	13.131
Was offered basuco	(-30.462, 44.731)	(-28.141, 52.844)
	21.331	-1.895
Obtained marijuana online	(-21.058, 63.386)	(-45.750, 42.966)
	-5.253	-38.941
Obtained marijuana in person	(-43.469, 32.479)	(-81.007, 1.816)
	17.866	-15.044
Obtained marijuana through friends	(-19.675, 55.641)	(-54.970, 25.497)
	11.016	-6.409
Obtained marijuana other / missing	(-42.669, 65.789)	(-62.444, 50.340)
	-10.386	31.744
Obtained cocaine online	(-55.445, 33.324)	(-14.425, 77.491)
<u></u>	-36.220	2.257
Obtained cocaine in person	(-76.435, 4.051)	(-40.470, 45.501)
	-23.087	9.198
Obtained cocaine through friends	(-62.550, 18.830)	(-33.817, 53.913)
	6.944	0.659
Obtained cocaine other / missing	(-46.995, 60.127)	(-54.177, 56.094)
	5.904	-6.570
Obtained basuco online	(-52.398, 64.693)	(-64.359, 52.558)
	6.954	-2.979
Obtained basuco in person	(-38.588, 51.350)	(-51.529.44.456)
	3.254	16.780
Obtained basuco through friends	(-41.316.48.748)	(-32.026.64.190)
	-32.921	-19 285
Indirect utility (y)	(-57.618, -9.223)	(-50.865, 8.684)
	-43.459	-55.035
Indirect utility ²	(-55,296,-33,796)	(-68.781 - 43.371)
	-4.519	-3.825
Indirect utility ^{3}	(-7.805, -1.496)	(-8.125 - 0.392)
 ਸ	ndogenous	(0.120, 0.002)
E	17 776	95 060
Relative price marijuana	1(.(0)	33.808 (6.214, 60,600)
	(-9.730, 47.792)	(0.314, 09.090)
Relative price cocaine	35.868	14.712
-	(6.314, 69.690)	(-26.491, 51.190)
Relative price marijuana $\times u$	-165.608	-200.421
1	(-198.133, -135.220)	(-237.563, -163.980)
Relative price cocaine $\times u$	-200.421	-189.935
1 0		

	(-237.563, -163.980) $(-265.410, -122.475)$
Observations	167

110

Notes: Posterior median coefficients from the Bayesian EASI system structural regressions. Estimates are cluster-specific, where the assignment is obtained automatically through our finite mixture procedure. 95% posterior quantile credibility intervals are presented underneath the coefficients.

Figure B.1: Trace plots of price elasticities of demand implied by EASI system estimates



Notes: Full trace of drawn price elasticity of demand parameter values (own and crossed between illicit drugs). Dashed line represents median of chains, dotted line provides the 95% HPD for each parameter, and a solid line at 0 is drawn for reference. Single chain run of 10000 after a burn-in window of 5000 iterations.

	5	2				
"Safe" Cluster	Share of Marijuana	Share of Cocaine	Relative price marijuana	Relative price cocaine	Relative price marijuana $~\timesy$	Relative price cocaine $\times y$
Share of Marijuana	1.000					
Share of Cocaine	$-0.665 \ (-0.786, -0.148)$	1.000				
Relative price marijuana	0.023 (-0.075, 0.119)	$0.020 \\ (-0.117, 0.148)$	1.000			
Relative price cocaine	$0.032 \ (-0.087, 0.148)$	$0.041 \\ (-0.172, 0.234)$	0.579 $(0.540, 0.615)$	1.000		
Relative price marijuana $~\timesy$	-0.133 (-0.448, 0.230)	-0.173 (-0.556, 0.293)	-0.011 (-0.067, 0.048)	-0.082 ($-0.140, -0.024$)	1.000	
Relative price cocaine $\times y$	-0.197 (-0.551, 0.214)	-0.153 (-0.600, 0.385)	-0.079 (-0.138, -0.021)	-0.079 (-0.137, -0.019)	0.612 (0.576, 0.647)	1.000
"Addict" Cluster	Share of Marijuana	Share of Cocaine	Relative price marijuana	Relative price cocaine	Relative price marijuana $\times y$	Relative price cocaine $\times y$
Share of Marijuana	1.000					
Share of Cocaine	0.992 $(0.982, 0.996)$	1.000				
Relative price marijuana	-0.114 (-0.196, -0.036)	-0.128 (-0.207, -0.048)	1.000			
Relative price cocaine	-0.156 ($-0.240, -0.073$)	-0.140 (-0.223, -0.051)	0.579 $(0.540, 0.615)$	1.000		
Relative price marijuana $\times y$	0.844 (0.808, 0.876)	0.876 (0.839, 0.910)	-0.011 (-0.067, 0.048)	-0.082 ($-0.140, -0.024$)	1.000	
Relative price cocaine $\times y$	0.932 $(0.909, 0.951)$	0.905 ($0.863, 0.933$)	-0.079 (-0.138, -0.021)	-0.079 (-0.137, -0.019)	0.612 (0.576, 0.647)	1.000
Notes: Table provides posteric underneath the estimated unre	or median of lower-trian estricted coefficients.	gular correlation mat	rix elements from Bayesian e	stimates. Highest posterio	: density (HPD) intervals covering	g 95% probability are presented

Table B.3: Bayesian estimates of system correlation matrix from EASI model across identified clusters

Good demand	Price Marijuana	Price Cocaine	Price Basuco		
Frequentist OLS					
<u>۲</u>	-0.9744	-0.0132	-0.0118		
Marijuana	$\left(-0.9955, -0.9507 ight)$	$\left(-0.0310, 0.0030 ight)$	$\left(-0.0280, 0.0039 ight)$		
Cocaino	-0.1277	-0.9728	0.0773		
Cocame	(-0.2606, 0.0017)	(-1.1258, -0.8093)	$\left(-0.0268, 0.1953 ight)$		
D	-0.3550	0.3581	-0.9194		
Basuco	(-0.9067, 0.1764)	(-0.1227, 0.8833)	(-1.3157, -0.5058)		
Frequentist 2SLS					
	-0.9617	-0.0256	-0.0152		
Marijuana	(-0.9912, -0.9338)	(-0.0482, -0.0016)	$\left(-0.0379, 0.0055 ight)$		
Cassing	-0.2298	-1.5257	0.7263		
Cocame	(-0.4270, -0.0311)	$\left(-2.1373, -0.9626 ight)$	(0.1589, 1.3445)		
Л	-0.3574	3.2823	-3.7030		
Basuco	(-1.1399, 0.4179)	(0.7246, 6.0796)	(-6.3126, -1.3334)		

Table B.4: Frequentist price elasticities of demand for the full sample of consumers

Notes: Full sample includes 1,236 consumers. For frequentist estimators, intervals are 95% percentile-*t* intervals from 1000 bootstrap replications. For Bayesian estimators, 95% highest posterior density (HPD) intervals are provided.

Good demand	Price Marijuana	Price Cocaine	Price Basuco		
Frequentist OLS					
	-0.9374	-0.0205	-0.0309		
Marijuana	(-0.9660, -0.9093)	(-0.0422, 0.0012)	(-0.0517, -0.0097)		
Comino	-0.2135	-1.0313	0.2010		
Cocame	(-0.3666, -0.0543)	(-1.2392, -0.8226)	$\left(0.0517, 0.3478 ight)$		
Deguee	-1.3104	0.8832	-0.7802		
Basuco	(-1.9986, -0.5760)	(0.2037, 1.5598)	(-1.2045, -0.3269)		
Frequentist 2SLS					
7.6.11	-0.9352	-0.0387	-0.0139		
Marijuana	(-0.9695, -0.9000)	(-0.0690, -0.0062)	(-0.0440, 0.0163)		
Cossino	-0.3577	-1.4700	0.7884		
Cocame	(-0.5955, -0.1172)	(-2.1777, -0.8098)	(0.1574, 1.4261)		
Destroe	-0.7452	3.5092	-4.0316		
Basuco	(-1.7570, 0.3027)	(0.6723, 6.3652)	(-6.9141, -1.5811)		
	Bayesia	an Censored			
	-0.9842	-0.0116	0.0004		
Marijuana	(-1.0104, -0.9586)	(-0.0339, 0.0114)	(-0.0044, 0.0053)		
Comino	-0.1330	-0.9080	0.0022		
Cocame	$\left(-0.3452, 0.0699 ight)$	(-1.0920, -0.7225)	$\left(-0.0335, 0.0386 ight)$		
Deguee	0.2690	0.1306	-1.3144		
Basuco	(-2.1879, 2.6402)	(-1.8721, 2.2195)	(-3.4434, 1.0741)		
Bayesian Censored with Endogeneity					
	-0.9617	-0.0372	0.0016		
Marijuana	(-0.9968, -0.9251)	(-0.0720, -0.0009)	(-0.0053, 0.0089)		
Coccino	-0.3254	-0.7462	0.0482		
Cocame	(-0.6292, -0.0462)	(-1.0506, -0.4085)	$\left(-0.1007, 0.1911 ight)$		
D	0.7953	2.7265	-4.4424		
Basuco	$\left(-2.7469, 3.9169 ight)$	(-5.5409, 10.9176)	(-13.0818, 3.7845)		

Table B.5: Price elasticities of demand for the sub-sample of consumers from the "safe" cluster

Notes: Identified Safe cluster sample includes 1202 consumers. For frequentist estimators, intervals are 95% percentile-t intervals from 1000 bootstrap replications. For Bayesian estimators, 95% highest posterior density (HPD) intervals are provided.

Covariate	T-statistic	P-value	Confidence Interval
Share of Marijuana	-18.975	2.695 E-20	(-0.822, -0.663)
Share of Cocaine	-2.135	0.039	(-0.114, -0.003)
Share of Basuco	18.341	7.039E-19	(0.712, 0.890)
Price paid for Marijuana	-0.989	0.329	(-0.256, 0.088)
Price paid for Cocaine	-0.593	0.557	(-0.154, 0.085)
Price paid for Basuco	1.655	0.107	(-0.139, 1.353)
Drug Expenditure	0.845	0.404	(-0.037, 0.089)
Dealer Presence	2.990	0.005	(0.075, 0.392)
Medium Risk	-0.819	0.418	(-0.086, 0.036)
High Risk	0.365	0.717	(-0.069, 0.100)
Consumer in network	8.812	4.217 E-18	(0.047, 0.074)
Female	-2.339	0.025	(-0.251, -0.018)
Both parents at home	-0.665	0.511	(-0.154, 0.078)
Medicinal marijuana products	-1.275	0.211	(-0.266, 0.061)
Good physical health	-2.957	0.006	(-0.437, -0.081)
Good meantal health	-1.563	0.127	(-0.314, 0.041)
Years of education	-6.150	4.884 E-07	(-5.149, -2.593)
Head of household	-0.043	0.966	(-0.178, 0.170)
Medium SES	-4.499	6.484 E-05	(-0.377, -0.143)
High SES	-0.955	0.346	(-0.090, 0.032)
Working status	0.579	0.566	(-0.122, 0.220)
Age minus 30	4.101	2.426E-04	(5.109, 15.147)
Codependent substance use	2.192	0.035	(0.007, 0.178)
Metropolitan area	0.151	0.881	(-0.161, 0.187)
Time using marijuana	0.149	0.882	(-4.522, 5.238)
Time using cocaine	0.831	0.412	(-2.215, 5.277)
Time using basuco	7.166	3.086E-08	(10.984, 19.690)
Drug captures	0.567	0.574	(-0.422, 0.750)
Access to marijuana	-0.943	0.353	(-0.088, 0.032)
Access to cocaine	18.697	1.138E-68	(0.202, 0.249)
Access to basuco	32.912	7.442 E- 170	(0.446, 0.502)
Offered marijuana	-0.651	0.519	(-0.167, 0.086)
Offered cocaine	5.385	4.147 E-06	(0.194, 0.429)
Offered basuco	11.435	1.461E-13	(0.540, 0.772)

 Table B.6: Balance of covariates comparing Addict and Safe clusters

Notes: T-statistic and P-values from a mean difference test across clusters (using different sample sizes). 95% confidence intervals of the mean estimate are also presented, where the difference is computed as "Addict" minus "Safe" cluster.



Figure B.2: ACF plots of price elasticities of demand implied by EASI system estimates

Notes: Autocorrelation plots for price elasticity of demand parameters (own and crossed between illicit drugs). Dashed line represents critical values for significance of correlation at a given lag. Single chain run of 10000 after a burn-in window of 5000 iterations.

Figure B.3: Density plots of equivalent variation following a price change in marijuana implied by EASI system estimates from "safe" cluster (annual USD)



Notes: Full posterior density over equivalent variation in 2019 USD\$ after changes in the price of marijuana and complete access to dealers following legalization of marijuana. Dashed line represents median of chains, dotted line provides the 95% HPD for each parameter, and a solid line at 0 is drawn for reference. Single chain run keeping 10000 draws after a burn-in window of 5000 iterations, discarding every 10 draws.

Figure B.4: Density plots of government revenue following a price change in marijuana implied by EASI system estimates from "safe" cluster (annual USD million)



Notes: Full posterior density over total annual government revenue given in millions of 2019 USD\$ after changes in the price of marijuana and complete access to dealers following legalization of marijuana. Dashed line represents median of chains, dotted line provides the 95% HPD for each parameter, and a solid line at 0 is drawn for reference. Single chain run keeping 10000 draws after a burn-in window of 5000 iterations, discarding every 10 draws.

Figure B.5: Density plot of change in dealer revenue following a price change in marijuana implied by EASI system estimates from "safe" cluster (annual USD million)



Notes: Full posterior density over change in total annual dealer revenue given in millions of 2019 USD\$ after changes in the price of marijuana and complete access to dealers following legalization of marijuana. Dashed line represents median of chains, dotted line provides the 95% HPD for each parameter, and a solid line at 0 is drawn for reference. Single chain run keeping 10000 draws after a burn-in window of 5000 iterations, discarding every 10 draws.

Figure B.6: Density plot of percentage change in number of users required to offset dealer revenue change following a price change in marijuana as implied by EASI system estimates from "safe" cluster



Notes: Full posterior density over the percentage change in the number of users required to offset the total change in annual dealer revenue after changes in the price of marijuana and complete access to dealers following legalization of marijuana. Full posterior density over change in total annual dealer revenue given in millions of 2019 USD\$ after . Dashed line represents median of chains, dotted line provides the 95% HPD for each parameter, and a solid line at 0 is drawn for reference. Single chain run keeping 10000 draws after a burn-in window of 5000 iterations, discarding every 10 draws.

Figure B.7: Density plot of change in drug dealer marijuana profits following a price change in marijuana implied by EASI system estimates from "safe" cluster



Notes: Full posterior density over the change in total marijuana profits given in millions of 2019 USD\$ after changes in the price of marijuana and complete access to dealers following legalization of marijuana. Dashed line represents median of chains, dotted line provides the 95% HPD for each parameter, and a solid line at 0 is drawn for reference. Single chain run keeping 10000 draws after a burn-in window of 5000 iterations, discarding every 10 draws.